

# DTP, DCTD TUMOR REPOSITORY

A CATALOG OF IN VITRO CELL LINES, TRANSPLANTABLE  
ANIMAL AND HUMAN TUMORS AND MICROARRAYS

**Operated by Charles River Laboratories, Inc.  
under contract to the Biological Testing Branch for  
The National Cancer Institute at Frederick  
Frederick, Maryland 21702-1201**

Sponsored by:

Biological Testing Branch  
Developmental Therapeutics Program  
Division of Cancer Treatment and Diagnosis  
National Cancer Institute  
National Institutes of Health

[www.dtp.nci.nih.gov](http://www.dtp.nci.nih.gov)

UPDATED:03/2012.

**DCTD Tumor Repository**

**Table of Contents**

INTRODUCTION.....	4
MATERIAL TRANSFER AGREEMENT-A.....	7
Cell lines maintained in the NCI-DCTD Repository .....	7
SHIPMENT OF TUMORS .....	9
SUBMISSION OF TUMORS FOR CRYOPRESERVATION .....	9
MOUSE TUMORS FROM THE JACKSON LABORATORY.....	9
FREEZING PROCEDURE .....	10
RECOMMENDED THAWING PROCEDURE.....	10
BACTERIAL AND VIRAL MONITORING OF CRYOPRESERVED TISSUES.....	11
<i>IN VITRO</i> ESTABLISHED CELL LINES:.....	11
HUMAN TUMORS.....	13
HAMSTER TUMORS .....	19
GUINEA PIG TUMORS.....	21
MOUSE TUMORS.....	23
ADDENDUM A: MOUSE TUMORS LISTED BY HISTOLOGICAL TYPE .....	24
ADDENDUM B: MOUSE TUMORS LISTED BY HOST STRAIN* .....	26
ADDENDUM C: OTHER MURINE MODELS.....	28
MOUSE TUMORS FROM THE JACKSON LABORATORY.....	43
RABBIT TUMORS.....	46
RAT TUMORS .....	48
RAT TUMORS FROM DR. ROBERT NOBLE (ENDOCRINE-RESPONSIVE).....	53

<i>IN VITRO</i> ESTABLISHED CELL LINES.....	57
HUMAN IN VITRO CELL LINES.....	58
NIH LICENSED CELL LINES.....	61
NCI ANTI-CANCER CELL LINE PANEL.....	62
NONHUMAN IN VITRO CELL LINES.....	66
YEAST STRAINS.....	67
INDEX .....	69

Page

## INTRODUCTION

The Division of Cancer Treatment and Diagnosis (DCTD), National Cancer Institute, has maintained since the early 1960s a low temperature repository of transplantable *in vivo*-derived tumors and *in vitro*-established tumor cell lines from various species. Currently located at the National Cancer Institute at Frederick in Frederick, Maryland, the DCTD Tumor Repository\* serves as a resource for viable, contaminant-free experimental tumor lines, many of which are not obtainable elsewhere. The Repository makes these materials available to qualified investigators as a service to the research community.

The Repository's tumor collection contains a wide variety of frozen types of human and animal origin. Virtually all of the human tumors are xenografts grown in athymic nude mice, although there are some that grow in conditioned rats or in hamster's cheek pouch. Several mouse leukemia lines in the collection are resistant to single drugs of varying modes of action. Multidrug-resistant lines are also available. In addition, the collection includes variant sublines of B16 melanomas that exhibit a different degree of metastasis to various organs.

The tumors in this catalog are categorized by species, namely, human, hamster, guinea pig, mouse, rabbit and rat. Within animal species, the list is in alphabetical order by tumor designation. Tumors with numeric designations are listed at the end. Human tumors are grouped by tumor type.

We request that the DCTD Tumor Repository, National Cancer Institute at Frederick, Frederick, Maryland, be cited in publications as the source of tumor materials. We also request that reprints of publications be furnished to the Repository.

---

\*Previous contract locations of the Tumor Repository include Microbiological Associates, Inc., Bethesda, MD; Arthur D. Little, Inc., Cambridge, MA; and Mason Research Institute, Worcester, MA.

## DTP, DCTD, NCI Repository - Ordering Procedures and Material Transfer Agreement-A

### Tumor Fragments, Cell Lines and Yeast

Tumor materials are furnished to qualified investigators affiliated only with recognized research laboratories. Items 1-3 below are required in order to receive material send all items to K. Gill at address below.

- 1) **Send a Letter** of Request on official institutional letterhead.
- 2) Provide a Purchase Order or **method of payment** details for Visa, MasterCard, American Express; or send a P.O. #; or Check; or indicate there will be a Wire Transfer payment.
- 3) Send the Material Transfer Agreement (**MTA with signatures**) affixed from both the requestor and authorizing official at your Institution (required by NCI). Please print or type this document

Request will be processed after receipt of all three items above. Legible scanned and emailed MTA paperwork will be accepted as well as courier or mailed paperwork, please no faxed MTAs. Send all paperwork to:

Ms. Katherine Gill  
 Biological Testing Branch  
 DTP, DCTD, NCI-Frederick  
 P. O. Box B,  
 1050 Boyles Street  
 Frederick, MD 21702-1201

T: 301-624-1248 (**new**)  
 F: 301-631-3027  
 E-mail all MTA paperwork & correspondence to:  
[gillk@mail.nih.gov](mailto:gillk@mail.nih.gov)

The Letter should briefly discuss either the requested material, research project or indicate method of payment. Newly requested material or MTA renewal will require completion of a new MTA. Multiple cell lines can be ordered using a single MTA. Clearly identify each item under #1 on the MTA, or on an addendum page. MTAs are active for a period of three years.

Re-orders by the same investigator for previously received material should indicate the MTA number of the earlier request in an email or letter of request, along with method of payment information.

The following fees include shipping in those cases where standard delivery methods can be used.

*NOTE: The rising cost of international transportation necessitates the addition of a shipping recovery fee of \$150.00 to International recipients to help defray shipping costs. Exception: Canadian surcharge of \$100.00.*

	NCI/NIH Investigators (MD campuses only) & Fed. Government	Academia & Non-profits Domestic & International	Commercial entities Domestic & International
<b>Cell or Tumor Lines</b>			
Per cryopreserved vial	N/A	\$150.00	\$200.00
NCI Anti-cancer cell line panel	N/A	\$6,700.00	\$8,850.00

*Complete panel is 60 cell lines, commercial entities will not receive five NCI-H lines accept through licensing application, cost will be adjusted by 5 lines.*

	NCI/NIH (MD campuses only) & Fed. Gov't.	Academia & Non-profits Domestic/International	Commercial entities Domestic & International
<b>Yeast Strains:</b>			
One strain	N/A	\$150.00	\$200.00
Complete set (16 strains)	N/A	\$1,800.00	\$2,400.00

**International Recipients:** The DCTD Tumor Repository obtains U.S. Exportation Declarations for each shipment. Recipients must obtain the applicable Import permits as required by the recipient's country. Send the Import document or permit number so we may obtain Export papers. Retaining a Broker to get your shipment through Customs is strongly suggested.

In cases where standard shipping methods are not applicable, the recipient will be contacted to cover all excess charges associated with shipping. Please contact NCI in advance to determine your eligibility for standard shipping rates. Material will be sent freight prepaid.

Inquiries regarding material availability, W-9s and Invoicing should be directed to:

Jane Shelton      T: 301 846-5748      F: 301 846-6941      E: [sheltonmj@mail.nih.gov](mailto:sheltonmj@mail.nih.gov)

Shipping questions should be directed to:  
 Vicky Clark      T: 301 846-7003      F: 301 846-6941      E: [clarkvj@mail.nih.gov](mailto:clarkvj@mail.nih.gov)

Scientific questions should be directed to:  
 Christine Pacula-Cox      T: 301 624-1254      F: 301.631.3027      E: [paculac@mail.nih.gov](mailto:paculac@mail.nih.gov)

**DTP, DCTD, NCI Tumor Repository Ordering Procedures**  
Cell Lines, Fragment Tissue, Yeast, TARP microarrays

**Purchase Order Mail To:**

Charles River Labs.

c/o **Kathy Gill** (or) Email to: [gillk@mail.nih.gov](mailto:gillk@mail.nih.gov)

BTB, DTP, DCTD, NCI

P. O. Box B

1050 Boyles Street,

Frederick, MD 21702-1201

Phone: 301.624.1248 (new)

Fax: 301.631.3027

E-mail: [gillk@mail.nih.gov](mailto:gillk@mail.nih.gov)

**Payment goes to:**

Charles River Laboratories, Inc

GPO Box 27812

New York, NY 10087-7812

CRL Federal Tax ID # 76-0509980

**Charles River Laboratories is our contractor who will ship and invoice the**

**research material on behalf of the NCI.** They accept the following credit cards for remittance:  
VISA, MASTERCARD and AMERICAN EXPRESS.

Please provide the details when using a credit card. Purchase orders, purchase order numbers, checks  
and wire transfers **are also accepted.**

**If using a P.O. please send a hard copy by fax or mail.**

For W-9 information and invoicing questions please contact:

**Ms. Jane Shelton at:** [sheltonmi@mail.nih.gov](mailto:sheltonmi@mail.nih.gov) Phone: 301-846-5748 or

**Fax: 301-846-6941**

**INTERNATIONAL:**

The rising cost of international transportation necessitates the addition of a shipping recovery fee of \$150.00 to  
International recipients to help defray shipping costs. Exception: Canadian surcharge is \$100.00. These fees  
apply in cases where standard delivery methods can be used.

**ELECTRONIC FUNDS WIRE TRANSFER INFORMATION EFT/ACH WIRES**

**JP Morgan**

**New York, NY**

**ABA Number: 021000021**

**Account of: Charles River Laboratories Lock Box Account**

**DDA (Checking) Account Number: 799-761499** (new account number)

**Swift Number: CHASUS33**

**ACH HELP DESK: (800) 447-3593**

**WIRE HELP DESK: (866) 223-0359**

**\*\* Please note: JPM uses the same ABA Number for both wires and ACH Payments**  
**CTX Format required to utilize EFT/ACH**

**The full invoice amount is to be paid; any bank wire fees incurred are at the purchaser's expense.**

# National Cancer Institute

## MATERIAL TRANSFER AGREEMENT-A Cell lines maintained in the NCI-DCTD Repository

This Material Transfer Agreement ("MTA") has been adopted for use by the National Cancer Institute ("NCI") for transfers of cell lines from the Division of Cancer Treatment and Diagnosis ("DCTD") Tumor Repository ("Research Material"). The DCTD Tumor Repository has maintained, since the early 1960's, a low temperature repository of transplantable tumor and tumor cell lines from various species. The Repository serves as a resource for experimental tumor lines from various species, many of which are not obtainable elsewhere. The Repository makes these Materials available as a service to the Research Community.

Recipient: \_\_\_\_\_  
Name of Recipient Investigator and Recipient Institution

1. NCI agrees to transfer to Recipient named above the following Research Material:

\_\_\_\_\_  
(use an attachment page if necessary)

2. **THIS RESEARCH MATERIAL MAY NOT BE USED IN HUMAN SUBJECTS.** The Research Material will only be used for research purposes by Recipient's investigator in his/her laboratory, for the research project described below, under suitable containment conditions. This Research Material will not be used for commercial purposes such as production or sale. Recipient agrees to comply with all Federal rules and regulations applicable to the Research Project and the handling of the Research Material. These samples are being provided in a manner that does not allow for direct identifiable patient information to the Recipient, and therefore do not constitute Human Subject Research as defined in 45 CFR Part 46, "Protection of Human Subjects".

3. This Research Material will be used by Recipient's investigator solely in connection with the following research project ("Research Project") described with specificity as follows (use an attachment page if necessary):

\_\_\_\_\_  
\_\_\_\_\_

4. In all oral presentations or written publications concerning the Research Project, Recipient will acknowledge NCI's contribution of this Research Material unless requested otherwise. To the extent permitted by law, Recipient agrees to treat in confidence, for a period of three (3) years from the date of its disclosure, any of NCI's written information about this Research Material that is stamped "**CONFIDENTIAL**," except for information that was previously known to Recipient or that is or becomes publicly available or which is disclosed to Recipient without a confidentiality obligation. Any oral disclosures from NCI to Recipient shall be identified as being **CONFIDENTIAL** by notice delivered to Recipient within ten (10) days after the date of the oral disclosure. Recipient may publish or otherwise publicly disclose the results of the Research Project, but if NCI has given **CONFIDENTIAL** information to Recipient such public disclosure may be made only after NCI has had thirty (30) days to review the proposed disclosure to determine if it includes any **CONFIDENTIAL** information, except when a shortened time period under court order or the Freedom of Information Act pertains.

5. This Research Material represents a significant investment on the part of NCI. Recipient's investigator therefore agrees to retain control over this Research Material and further agrees not to transfer the Research Material to other people not under her or his direct supervision without advance written approval of NCI. NCI reserves the right to distribute the Research Material to others and to use it for its own purposes. When the Research Project is completed or three (3) years have elapsed, whichever occurs first, the Research Material will be disposed of as directed by NCI.

6. This Research Material is provided as a service to the research community. IT IS BEING SUPPLIED TO RECIPIENT WITH NO WARRANTIES, EXPRESS OR IMPLIED, INCLUDING ANY WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. NCI makes no representations that the use of the Research Material will not infringe any patent or proprietary rights of third parties.

7. Recipient may retain title to the patent rights in inventions made by its employees in the course of the Research Project. Recipient agrees not to claim, infer, or imply Governmental endorsement of the Research Project, the institution or personnel conducting the Research Project or any resulting product(s). Unless prohibited by law from doing so, recipient agrees to hold the United States Government harmless and to indemnify the Government for all liabilities, demands, damages, expenses and losses arising out of Recipient's use for any purpose of the Research Material.

8. The undersigned Recipient expressly certifies and affirms that the contents of any statements made herein are truthful and accurate.

9. This MTA shall be construed in accordance with Federal law as applied by the Federal courts in the District of Columbia.

Date: \_\_\_\_\_  
Recipient **Investigator's Signature and Title**

Date: \_\_\_\_\_  
**Authorized Signature and Title**, for Recipient's Institution (**Note:** Authorized Signature has the authority to bind the Institution to the terms of this Material Transfer Agreement).

→ Recipient's Shipping Address:

Recipients Billing Address (if different):

→Recipient's Phone, Fax, E-mail:

Authorized Signature for NCI: \_\_\_\_\_ Date: \_\_\_\_\_  
**Melinda G. Hollingshead, D.V.M., Ph.D.**, Chief, BTB, DTP, DCTD, NCI-Frederick

NCI's Mailing Address:

Ms. Katherine Gill  
Biological Testing Branch  
DTP/DCTD/NCI  
P.O. Box B  
1050 Boyles Street  
Frederick, MD 21702-1201  
Phone: 301.624.1248  
Fax: 301.631.3027  
Email: [gillk@mail.nih.gov](mailto:gillk@mail.nih.gov)

## SHIPMENT OF TUMORS

The transplantable tumors are distributed as frozen vials of tumor tissues or cell suspension. Transplantable tumors as well as cell culture lines are shipped as frozen vials of tissues on dry ice. Each tumor shipment includes an information sheet showing, among other items, the proper tumor designation, cryopreserved date, *in vivo* host, etc.

Requested tumors are shipped two to three weeks after receipt of all completed paperwork. Domestic shipments leave the Repository no later than Wednesday in order to reach their destination on week days. Foreign shipments are sent according to final destination. Before shipment, the Repository notifies the Recipient of the waybill number and carrier information by e-mail or fax. Recipient must notify the Repository or make arrangements for receipt of the tumor lines, in the event that they will not be available to receive the shipment. An invoice for payment will follow and payment is due upon receipt.

## SUBMISSION OF TUMORS FOR CRYOPRESERVATION

Investigators who have unique and novel experimental tumor lines and wish to submit their tumors to the Repository for cryopreservation and storage should write a letter of intent to the Project Officer. Upon acceptance, the Project Officer will inform the investigator in writing, and will provide instructions on the procedure for shipping tumor materials to the Repository. Tumor tissues or cells (frozen or ambient) are preferred over tumor-bearing animals.

At the Repository, the tumor line(s) will be tested for viral and bacterial contamination. When proven "clean," the line(s) will be expanded, *in vivo* or *in vitro* as appropriate, for large batch cryopreservation. Viability and growth of the frozen tumors will be evaluated. The tumors will be included in the Repository's inventory, and upon joint approval of the submitting investigator and the Project Officer, they will be made available for distribution to the scientific community.

## MOUSE TUMORS FROM THE JACKSON LABORATORY

These tumors formerly were maintained and distributed by the Jackson Laboratory. The list of available tumors begins on page 39 of the DCTD Tumor Repository Catalog. They were cryopreserved at EG&G Mason Research Institute and are distributed only as vials of frozen tumor tissue. The required host animals for carrying the JAX tumors in serial transplantation may be obtained from:

Animal Resources  
The Jackson Laboratory  
600 Main Street  
Bar Harbor, ME 04609  
USA  
T: 800.422.MICE  
207.288.5845  
F: 207.288.6150

## **FREEZING PROCEDURE**

Solid tumors are frozen as 2 x 2 x 2 mm fragments suspended in a freezing medium. Ascites or tissue culture cells are frozen as single cell suspension at a concentration of  $10^6$ - $10^7$  cells per ml. The freezing medium consists of appropriate tissue culture growth medium plus 10% DMSO and 10% fetal bovine serum.

Aseptically harvested ascites tumors are diluted in the freezing medium at a concentration of  $10^6$ - $10^7$  cells per ml. One ml suspension is pipetted into each 2 ml vial (Nunc cryotube). The vials are screw-capped tightly and labeled with Repository number. Tissue culture cells are prepared in a similar manner. For solid tumors, the aseptically excised tumor tissue is cut into 2 x 2 x 2 mm fragments after freeing it of necrotic materials. The fragments are placed in vials containing 1.5 ml of freezing medium.

The processed tumors are frozen initially in a controlled slow-rate freezing apparatus at the rate of 0.5°C per minute to -20°C and 1°C per minute to -80°C. The frozen vials are stored in specific locations in the liquid nitrogen freezers in the Repository after the controlled freezing cycle.

## **RECOMMENDED THAWING PROCEDURE**

Frozen tumor cells or tissues received from the Repository should be kept frozen at -70°C or lower until ready for use. For prolonged storage (more than two days), liquid nitrogen freezers are recommended.

The vials in which the cell lines are stored are reliable; however, they are very susceptible to contamination if thawed in a contaminated water bath. Thawing should be rapid, i.e., within 60-90 seconds. Place the vial in a warm water bath at 37-40°C and agitate vigorously to thaw. Immerse the vial in 70% ethanol before uncapping. Implant immediately after thawing. The concentration of DMSO is not toxic to tissues and implantation may be made directly from the vial.

For tissue culture, transfer the contents of the vial into a petri dish or a flask containing at least 10 volumes of the recommended culture medium and incubate. In order to remove the protective freezing additive (DMSO) from the culture medium, we suggest that the culture medium be changed 24 hours after seeding. If it is desired that DMSO be removed immediately, centrifuge the diluted suspension at approximately 125 x g for 10 minutes, discard the supernatant, and resuspend the cells in an appropriate volume of growth medium.

**CAUTION:** We strongly recommend wearing protective glasses or face shields when thawing tissues in glass vials.

**TUMOR TRANSPLANTATION:** It is recognized that transplantable tumor systems are experimental tools for investigators in scientific disciplines other than tumor biology or transplantation immunogenetics. Therefore, we encourage investigators with limited transplantation experience to contact the Tumor Repository for more detailed information on techniques.

## **BACTERIAL AND VIRAL MONITORING OF CRYOPRESERVED TISSUES**

In addition to testing all freeze-runs for bacterial contamination, cryopreserved tissues are tested for viral contamination by the MAP test. The viruses tested for are as follows: pneumonia virus of mice (PVM), reo virus-type 3 (Reo 3), Theiler's virus, murine encephalitis (GD VII), polyoma (Poly), minute virus of mice (MVM), mouse hepatitis virus (MHV), lymphocytic choriomeningitis (LCM), Sendia virus (Send), ectromelia, mouse pox (Ectro), lactic dehydrogenase virus (LDH).

### **IN VITRO ESTABLISHED CELL LINES:**

- A. **Quality Control and Characterization** - The quality control and characterization procedures for the incorporation of new cell lines into the Tumor Repository are as follows: Upon receipt, each cell line is immediately transferred to fresh antibiotic-free medium and cultured for one week, after which it is tested for mycoplasma (PPLO) contamination. Standard culture procedures under aerobic and anaerobic conditions, as well as the orcein staining procedure of Fogh, are used. The PPLO medium is extremely rich, and this procedure will also detect most bacterial and fungal contaminants.
- B. **Freezing and Storage** - The cell cultures are frozen in ampules containing 1.0 ml of cell suspension at  $2-6 \times 10^6$  cells/ml in fresh culture medium containing 10% DMSO. Freezing is performed as on page 6. Twenty-four hours after freezing, a representative ampule is removed, thawed, and viable cell count is performed, using the trypan blue dye exclusion procedure. The culture is also tested for its ability to initiate a heavy viable culture. Cell preparations which show less than 50% viability or poor growth are discarded and a new lot is prepared.
- C. **Recommended Procedure for Thawing Frozen Cell Cultures** - The vials in which the cell lines are stored are reliable; however, they are very susceptible to contamination if thawed in a contaminated water bath. The following procedures are provided to eliminate this problem.

Remove the ampule from the dry ice container and place it directly into a 37-40°C water bath (or vessel) of freshly drawn water containing an effective concentration of disinfectant. The thawing should be vigorous and rapid (within 40-60 seconds). As soon as the thawing is complete, remove the ampule from the water bath and immerse in 70% ethanol at room temperature. All of the operations from this point

should be carried out under strict aseptic conditions in a sterile room, cubicle, or hood.

Transfer the contents of the ampule (1 ml volume) into a 100 mm petri dish or 25 cm<sup>2</sup> flask containing 8-10 ml of the recommended culture medium, and incubate at the appropriate temperature and carbon dioxide level.

In order to remove the protective freezing additive (DMSO) from the culture medium, we suggest that the culture medium be changed 24 hours after thawing. If it is desired that the freezing additive be removed immediately or that a more concentrated cell suspension be obtained, centrifuge the above diluted suspension at approximately 125 x g for 10 minutes, discard the fluid, and resuspend the cells in an appropriate volume of growth medium.

## **HUMAN TUMORS**

<b>SPECIES: HUMAN</b>			
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>General Information</b>	<b>Species and/or Strain of Transplantability</b>
<b>BREAST</b>			
COO-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
DU4475	Mammary Carcinoma	Primary explant from cutaneous tumor nodule in region of mastectomy established <i>in vitro</i> by Dr. A.J. Langlois, Duke University Medical Center; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
ELL-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
HIG-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
MCF/7	Mammary Carcinoma	Primary explant from pleural effusate established <i>in vitro</i> by Dr. H.D. Soule, Michigan Cancer Foundation; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MDA-MB-436	Mammary Carcinoma	Primary explant from pleural effusate established <i>in vitro</i> by Dr. Relda Cailleau, M.D. Anderson Hospital and Tumor Institute; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MX-1	Mammary Carcinoma	Primary xenotransplant from an infiltrating duct carcinoma (CLO-G). Adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
MX-2	Mammary Carcinoma	Adapted to <i>in vivo</i> from <i>in vitro</i> established pleural effusate.	Nude Athymic Mice
SW-613	Mammary Carcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice
VAN-G	Mammary Carcinoma	Primary explant established <i>in vivo</i> in athymic nude mice by Dr. B. Giovanella, Stehlin Foundation.	Nude Athymic Mice
<b>LUNG</b>			
LX-1	Lung, undifferentiated carcinoma	Xenotransplant from a metastasis to subcutaneous tissue (DOY-G). The primary lung tumor was an oat cell carcinoma. Adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
COS-G	Lung, papillary carcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice

<b>SPECIES: HUMAN</b>			
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>General Information</b>	<b>Species and/or Strain of Transplantability</b>
<b>LUNG (continued)</b>			
H-MESO-1	Lung, mesothelioma	Xenotransplant from a primary tumor received from Dr. R.M. Williams and Dr. A. Rossini. Adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
H-MESO-1A	Lung, mesothelioma	H-MESO-1 converted to ascites form by Dr. A.E. Bogden.	Nude Athymic Mice
NCI-H23 H23	Lung, nonsmall cell, adenocarcinoma	Obtained from Dr. Adi Gazdar.	Nude Athymic Mice
NCI-H460 H460	Lung, nonsmall cell, epid.	Obtained from Dr. Adi Gazdar.	Nude Athymic Mice
MRI-H-165	Lung, squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-266	Lung, poorly differentiated carcinoma	Xenotransplant from a metastasis, adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
<b>COLON</b>			
CX-1 (HT-29)	Colon, adenocarcinoma	Primary, untreated adenocarcinoma (HT-29) adapted to <i>in vitro</i> cell culture by Dr. Jergen Fogh; then adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden. Secretes CEA.	Nude Athymic Mice
CX-2	Colon, carcinoma	Primary xenotransplant (CA-1) adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella. Received at MRI from Dr. A. Ovejera.	Nude Athymic Mice
CX-3	Colon, carcinoma		Nude Athymic Mice
CX-5	Colon, adenocarcinoma	Xenotransplant from an untreated metastasis (SQU-G) adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
GOB-G	Colon, adenocarcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
HCC-2998	Colorectal carcinoma	Obtained from Dr. I.J. Fidler.	Nude Athymic Mice
HCT-15	Colon, carcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice
KLO-G	Colon, adenocarcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
KM20L2	Colon, adenocarcinoma	Obtained from Dr. I.J. Fidler.	Nude Athymic Mice
MRI-H-194	Colon, adenocarcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
LOVO I	Colon, adenocarcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice

<b>SPECIES: HUMAN</b>			
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>General Information</b>	<b>Species and/or Strain of Transplantability</b>
<b>COLON (continued)</b>			
LOVO II	Colon, adenocarcinoma	Established from <i>in vitro</i> line.	Nude Athymic Mice
MRI-H-250	Colon, carcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
<b>MELANOMA</b>			
BOW-G	Melanosarcoma	Xenotransplant from metastasis adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
DEAC-7	Melanoma	Received as cryopreserved ampules from Dr. S. Warren and Dr. W.B. Patterson.	Hamster Cheek Pouch
FO #1	Melanoblastoma	Adapted to <i>in vivo</i> transplantation (FOS-G) by Dr. B. Giovanella.	Nude Athymic Mice
NIS-G	Melanosarcoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
TRI-G	Melanoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
WIL-G	Melanoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
MRI-H-121B	Melanoma, malignant	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-187	Melanoma, epithelioid, melanotic	Xenotransplant from metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-221	Melanoma, malignant	Xenotransplant from metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-255	Melanoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
<b>CERVIX</b>			
MRI-H-130	Cervix, squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-177	Cervix, squamous cell carcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-186	Cervix, invasive, large cell, nonkeratinizing, squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-196	Cervix, poorly differentiated squamous cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice

<b>SPECIES: HUMAN</b>			
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>General Information</b>	<b>Species and/or Strain of Transplantability</b>
<b>CERVIX (continued)</b>			
MRI-H-215	Cervix, invasive, large cell, nonkeratinizing, poorly differentiated, epidermoid carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
<b>KIDNEY</b>			
MRI-H-121	Kidney, carcinoma	Xenotransplant from a metastasis adapted to <i>in vivo</i> transplant by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-166	Kidney, transitional cell carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
<b>ENDOMETRIUM</b>			
MRI-H-147	Endometrium, carcinoma, Müllerian duct	Primary xenotransplant adapted <i>in vivo</i> trans-plantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-171	Endometrium, carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-220	Endometrium, carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-253	Endometrium, carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
<b>OVARY</b>			
MRI-H-207	Ovary, undifferentiated carcinoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-227	Ovarian Adenocarcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. R. Hunter, University of Massachusetts Medical School.	Nude Athymic Mice
MRI-H-258	Ovarian Adenocarcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. R. Hunter, University of Massachusetts Medical School.	Nude Athymic Mice
MRI-H-273	Ovarian Carcinoma	Originated from metastasis. Established <i>in vivo</i> by Dr. A.E. Bogden. Received from New England Deaconess Hospital.	Nude Athymic Mice
MRI-H-1834	Ovarian Carcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. R. Hunter, University of Massachusetts Medical School.	Nude Athymic Mice
SWA-G	Ovarian Carcinoma	Xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice

<b>SPECIES: HUMAN</b>			
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>General Information</b>	<b>Species and/or Strain of Transplantability</b>
<b>SARCOMA</b>			
HS-1	Sarcoma	No historical information available.	Conditioned Rats
OGL-G	Sarcoma, spindle cell, periosteal osteogenic	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
DEL-G	Sarcoma	Primary xenotransplant adapted to <i>in vivo</i> transplantation by Dr. B. Giovanella.	Nude Athymic Mice
<b>EPIDERMOID</b>			
HEP-3	Epidermoid carcinoma	No historical information available.	Conditioned Rats
DEAC-1	Mucoepidermoid carcinoma	Received as cryopreserved ampules from Dr. S. Warren and Dr. W.B. Patterson.	Hamster Cheek Pouch
<b>CNS</b>			
SF 295	Glioblastoma	Obtained from Dr. Rosenblum.	Nude Athymic Mice
<b>MISCELLANEOUS</b>			
CWR-22	Prostate, adenocarcinoma	Received from Dr. T. Pretlow, <i>in vivo</i> cultivation requires testosterone supplementation. Not an <i>in vitro</i> cell line.	Nude Athymic Mice
DAU	Burkitt's lymphoma	Received from Dr. T. Griffin, adapted to <i>in vivo</i> transplantation by Dr. A.E. Bogden.	Nude Athymic Mice
MRI-H-254	Stomach, adenocarcinoma	No historical information available.	Nude Athymic Mice
MRI-H-1579	Prostate Adenocarcinoma	Primary explant established <i>in vivo</i> by Dr. A.E. Bogden. Received from Dr. Blute, St. Vincent Hospital, Worcester, MA.	Nude Athymic Mice

**Note: *Human In Vitro Established Cell Lines are on pages 59-62.***

## **HAMSTER TUMORS**

<b>SPECIES: HAMSTER</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Fibrosarcoma	Fibrosarcoma	Ascites	Not Specified	
H-12	Mesothelioma	Solid	Golden Syrian	
H-75	Mesothelioma	Solid	Golden Syrian	
Islet Cell	Pancreatic Adeno- carcinoma	Solid	Golden Syrian	
Lymphosarcoma	Lymphosarcoma	Ascites	Not Specified	
Melanoma	Melanotic Melanoma	Solid	Not Specified	
Pan #1 (Fortner)	Pancreatic Duct Adeno- carcinoma	Solid	Not Specified	
SB #1 (Fortner)	Small Bowel Adeno- carcinoma	Solid	Not Specified	
TG1-4	Mesothelioma	Solid	Golden Syrian	
TS1-4	Epidermoid Carcinoma	Solid	Golden Syrian	
10-24	Mesothelioma	Ascites	Golden Syrian	
1382J	Liver Carcinoma	Solid	Golden Syrian	
2309V	Pancreatic Islet $\beta$ Cell Adenocarcinoma	Solid	Golden Syrian	
4671	Pancreatic Duct Adeno- carcinoma	Solid	Golden Syrian	Line B is insulin- secreting
6973P	Leiomyosarcoma	Solid	Golden Syrian	
8721R	Renal Carcinoma	Solid	Golden Syrian	
8746Q	Uterine Adeno- carcinoma	Solid	Golden Syrian	
9242e	Parotid Acinar Cell Adenocarcinoma	Solid	Golden Syrian	
10838	Seminoma	Solid	Golden Syrian	
11348P	Pulmonary Squamous Cell Carcinoma	Solid	Golden Syrian	
11963V	Leiomyosarcoma	Solid	Golden Syrian	
22047	Adenocarcinoma	Solid	Golden Syrian	

## **GUINEA PIG TUMORS**

<b>SPECIES: GUINEA PIG</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Line 1	Hepatocarcinoma	Ascites	Strain 2	
Guinea Pig GP Line 10	Hepatocarcinoma	Ascites	Strain 2	
Nitrosamine-induced Hepatoma	Hepatoma	Solid	Strain 39	

## **MOUSE TUMORS**

Two addenda have been inserted in this section to facilitate identification or selection of mouse tumors by histologic type (Addendum A) and by mouse strain (Addendum B). A third (Addendum C) is a list of other models together with treatment information.

**ADDENDUM A: MOUSE TUMORS LISTED BY HISTOLOGICAL TYPE**

Adrenal

AT  
LAF<sub>1</sub>

Anaplastic Carcinoma

dbrB (Jax)

Bladder

FCB

Colon

CA07/A  
CA36/Ara C  
CA51  
Colon 26  
Colon 38

Ependymoblastoma

Ependymoblastoma

Fibrosarcoma

36257 TTT  
Hepatoma 129

38290 TTT  
Hepatoma 134

46362 TTT

46363 TTT

FB SAR  
SaD2 (Jax)

Glioma

Glioma 26  
Glioma 261

Hemangioendothelioma

36230 TLT  
42021 TCT  
42022 TST  
42052 TST  
42076 TST  
44316 TST  
44347 TST

Hepatoma

BW 7756 (JAX)  
H6 (JAX)  
Hepatoma 129  
Hepatoma 134

Inguinal

Krebs Ascites  
Krebs-2

Leukemias

C58/J Spont.  
C1498  
Egg/Mouse  
E Male/Gross  
Gross  
L1210  
L4946  
L5178Y  
P288  
P388  
P815  
P1534  
P1798  
RBL-n

Lung

ASB XIV  
C4461  
CAD2  
LC-12  
Lewis  
M4898  
Madison  
Nettesheim

Lymphoma &  
Lymphosarcoma

BL12  
EL-4 Male  
L18464  
LSTRA  
Mecca  
NK  
6C3HED

Mammary

Adenocarcinoma 755  
BW10232 (Jax)  
CE1460 MACA  
CH  
C3HBA (Jax)  
DBA/2 Spont. M114  
Ehrlich Ascites  
EMT-6  
Gross  
H2712 (Jax)  
Klein  
MA13C  
MA16C  
MC-n  
MCS-1  
MXT  
Spont. DBA/2

ADDENDUM A (continued)

Melanoma

B16  
Harding-Passey  
HP (Jax)

Nervous System

C1300 (Jax)  
Ependymoblastoma  
Glioma

Osteogenic

HE10734

Pancreas

PAN 02  
PAN 03

Pituitary

A+T  
BW8685 (Jax)  
BW8883 (Jax)  
T+T #15  
T+T #97

Plasmacytoma

ADJ-PC-n  
LPC-1  
MOPC-n  
MPC-n  
RPC-n  
YPC-1  
70429

Reticulum Cell

Friend Virus Leukemia  
M5076  
SJL/JW  
91632

Sarcoma

Lewis  
MA387  
METH-A  
MS-2  
S37  
S180  
Sa-1 (Jax)

Squamous

LC-12

Testicular

M5480

Teratosarcoma

LS402AX

Thymus

Reif-Allen

\*Refer to Inventory for details. A designation followed by n, e.g., MOPC-n, indicates that there is a series of tumors with this main designation, e.g., MOPC-4, MOPC-17, MOPC-21, etc.

ADDENDUM B (continued)

**ADDENDUM B: MOUSE TUMORS LISTED BY HOST STRAIN\***

INBRED HOSTS

<u>A/HE</u>	<u>BALB/c (cont'd)</u>	<u>C57BL/6 (cont'd)</u>
C4461 Hauschka Ascites Klein (TA3)	RPC- <u>n</u> S37 YPC-1 1247	C1498 Colon 38 EL-4 E Male Gross Ependymblastoma FCB
<u>A/J</u>	36257 TTT 38290 TTT 42021 TCT 44316 TST 44316 LTST 44347 TST 46363 TTT	Glioma 26 Glioma 261 L18464 Lewis Lung Lewis Sarcoma T241 LS402AX M5076 M5480 NK-Lymphoma PAN 02 PAN 03 RBL- <u>n</u> T+T #15 42022 TST 42052 TST 42076 TST 46362 TTT 91632
<u>AKR</u>	<u>CE</u> CE1460 MACA	
L4946 MA387 Mecca Reif-Allen	<u>C3H</u> C3HBA (Jax) FB SAR Gross Leukemia H2712 (Jax) HE 10734 Hepatoma 129 Hepatoma 134 J30237 Krebs Ascites Carcinoma Krebs 2 Carcinoma MA13C MA16C Mecca X5563 6C3HED 70429	
<u>BALB/c</u> ADJ-PC- <u>n</u> ASB XIV CA07/A CA36/Ara C CA51 Colon 26 EMT-6 Harding-Passey HP (Jax) LC-12 LPC-1 LSTRA M4898 Madison Lung MC- <u>n</u> METH-A Moloney Sarcoma MOPC- <u>n</u> MPC- <u>n</u> MS-1 MS-2 P1798	<u>C57BL/6</u> Adenocarcinoma 755 B16 BL12 BW 10232 (Jax)	<u>C57L/J</u> BW7756 (Jax) BW8883 (Jax)  <u>C57BR/cdj</u>  BW8685 (Jax)  <u>C58</u>  C58J/Spont.

ADDENDUM B (continued)

<u>DBA/1</u>	<u>DBA/2 (cont'd)</u>	<u>DBA/2 (cont'd)</u>
CaD1 (Jax)	Gross Mammary Adeno-	Spont. DBA/2 Mammary
dbrB (Jax)	carcinoma	T1699 (Jax)
S37 (Jax)	L1210	
S91 (Jax)	L5178Y	
T1703 (Jax)	Nettesheim	<u>SJL/J</u>
	P288	SJL/JW
	P329	
<u>DBA/2</u>	P388	<u>129</u>
CAD2	P815	
DBA/2 Spont. M114	P1534	LS402AX
Egg/Mouse Leukemia	S180	
Friend Virus Leukemia	SaD2 (Jax)	

F<sub>1</sub> HYBRIDS AND NON-INBRED HOSTS

<u>Swiss</u>	<u>LAF<sub>1</sub></u>	<u>CDF<sub>1</sub></u>
Ehrlich Ascites	AT	R- <u>n</u>
S180	LAF <sub>1</sub>	RC-2
	MST	102A
<u>BDF<sub>1</sub></u>	T+T #97	
		Various resistant lines of
MXT	<u>CAF<sub>1</sub></u>	L1210 and P388
Various resistant lines of L1210 and P388	Lymphoma-2	

\*Refer to Inventory for details. A designation followed by n, e.g., MOPC-n, indicates that there is a series of tumors with this main designation, e.g., MOPC-4, MOPC-17, MOPC-21, etc.

## **ADDENDUM C: OTHER MURINE MODELS**

### L1210 Lymphoid Leukemia

L1210/TSC (NSC-729)	L1210/Ara-C (NSC-63878)
L1210/MTX (NSC-740)	L1210/cis-DDP (NSC-119875)
L1210/6MP (NSC-755)	L1210/Anhydro Ara C (NSC-145668)
L1210/L-PAM (NSC-8806)	L1210/Ftorafur (NSC-148958)
L1210/NSC-19622	L1210/L-Alanosine (NSC-153353)
L1210/5FU (NSC-19893)	Note: Reo3 <sup>+</sup>
L1210/CTX (NSC-26271)	L1210/BCNU (NSC-409962)
L1210/DF8 (NSC-29630)	L1210/C95 (NSC-740, 755, 26271)
L1210/HU (NSC-32065)	L1210/FR3 DCM/R 100a
L1210/MeGAG (NSC-32946)	L1210/FR8/DCM
L1210/NSC-38280	L1210/RT8 (Folate Reductase)
L1210/DTIC (45388)	L1210/M-773
L1210/TIC (NSC-60339)	L1210/6MP/6TG

\*Treatment information, where available, is given in the following pages. When resistant lines are shipped, treatment information, if any, is included.

### P388 Lymphocytic Leukemia

P388/MTX (NSC-740)	P388/ADR (NSC-123127)
P388/Actinomycin D (NSC-3053)	P388/L-Alanosine (NSC-153353)
P388/DON (NSC-7365)	P388/Acivicin (NSC-163501)
P388/L-PAM (NSC-8806)	P388/Amsacrine (NSC-249992)
P388/5-FU (NSC-19893)	P388/Anthracenedione (NSC-287513)
P388/CPA (NSC-26271)	Note: Reo3 <sup>+</sup>
P388/Ara C (NSC-63878)	P388/Mitoxantrone (NSC-299195 + 301739)
P388/Daunomycin (NSC-82151)	P388/Ara-A + 2'dcF (NSC-404241 + 218321)
P388/5-Azacytidine (NSC-102816)	P388/BCNU (NSC-409962)
P388/DDP (NSC-119875) Note: Reo3 <sup>+</sup>	

### Other Resistant Leukemias

L5178/L-Ase R  
P288/MTX (NSC-740)  
P815/VLB (NSC-49842)

### Lewis Lung Carcinoma Only in Mice

LLC-Luc-GFP (LL-LUC-POL2)

DRUG-RESISTANT MURINE LEUKEMIAS - TREATMENT INFORMATION FOR LINES RECEIVED  
FROM SOUTHERN RESEARCH INSTITUTE AND ARTHUR D. LITTLE, INC.

Tumor Line	Host of Origin, Resistant Line	Passage Inoculum (i.p.)	Treatment Used with Serial Passage				Optimal Treatment to Check Degree of Resistance			
			NSC #	mg/Kg	Route	Schedule	NSC #	mg/Kg	Route	Schedule
L1210/TSC (NSC-729)	DBA/2 or CDF1	10 <sup>5</sup>	729	5.0	i.p.	Days 1-6	729	6.0	i.p.	Q3Hx8 Days 1,5,9
L1210/6-MP (NSC-755)	DBA/2	10 <sup>6</sup>	NONE				755	50.0	i.p.	QD1-9 days
L1210/L-PAM (NSC-8806)	BDF1	10 <sup>6</sup>	8806	7.5	i.p.	Day 2 only	8806	15.0	i.p.	Day 1 only
L1210/CPA (NSC-26271)	DBA/2	10 <sup>5</sup>	NONE				26271	265.0	i.p.	Day 1 only
L1210/HU (NSC-32065)	DBA/2 or CDF1	10 <sup>5</sup>	32065	130.0	i.p.	Days 1-6	32065	60.0	i.p.	Q3Hx8 Days 1,5,9
L1210/ARA-C (NSC-63878)	DBA/2 or hybrid	10 <sup>5</sup>	NONE				135962	125.0	i.p.	Day 1 only
L1210/DDP (NSC-119875)	DBA/2 or CDF1	10 <sup>6</sup>	119875	5.0	i.p.	Day 4 only	119875	8.0	i.p.	Day 1 only
L1210/BCNU (NSC-409962)	BDF1	10 <sup>5</sup>	NONE				409962	30.0	i.p.	Day 1 only
P388/MTX (NSC-740)	DBA/2 or CDF1	10 <sup>7</sup>	740	0.75	s.c.	Days 1-6	740	2.0	i.p.	QD1-9 days
P388/ACT-D (NSC-3053)	DBA/2 or CDF1	10 <sup>7</sup>	3053	0.2	i.p.	Day 4 only	3053	0.5	i.p.	Day 1 only
P388/L-PAM (NSC-8806)	BDF1	10 <sup>6</sup>	8806	7.5	i.p.	Day 2 only	8806	15.0	i.p.	Day 1 only
P388/5-FU (NSC-19893)	BDF1	10 <sup>7</sup>	19893	20.0	s.c.	Days 1-6	19893	25.0	i.p.	QD1-9 days
P388/CPA (NSC-26271)	BDF1	10 <sup>7</sup>	26271	100.0	s.c.	Day 4 only	26271	265.0	i.p.	Day 1 only
P388/VCR	BDF1	10 <sup>7</sup>	NONE				67574	1.5	i.p.	Days 1,5,9

Tumor Line	Host of Origin, Resistant Line	Passage Inoculum (i.p.)	Treatment Used with Serial Passage				Optimal Treatment to Check Degree of Resistance			
			NSC #	mg/Kg	Route	Schedule	NSC #	mg/Kg	Route	Schedule
(NSC-67574)										
P388/AZACYT (NSC-102816)	DBA/2 or CDF1	10 <sup>7</sup>	102816	40.0	i.p.	Day 4 only	102816	3.5	i.p.	QD1-9 days
P388/DDP (NSC-119875)	DBA/2 or CDF1	10 <sup>7</sup>	119875	4.5	i.p.	Days 1&5	119875	5.3	i.p.	Days 1,5,9
P388/ADR (NSC-123127)	BDF1	10 <sup>7</sup>	123127	6.0	i.p.	Day 2 only	123127	12.5	i.p.	Day 1 only
P388/ARA-A + 2'dcF (NSC-404241 + NSC-218321)	BDF1	10 <sup>6</sup>	404241 + 218321	125.0 .02	i.p.	Days 2-4	404241 + 218321	60.0 0.05	i.p.	Q3Hx8, Days 1,5,9
							<u>OR</u>			
							404241 + 218321	150.0 0.25	i.p.	QD1-9 days
P388/BCNU (NSC-409962)	CDF1	10 <sup>7</sup>	409962	25.0	i.p.	Day 2 only	409962	30.0	i.p.	Day 1 only

\*NSC-218321 thirty minutes before NSC-404241 each time.

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Adenocarcinoma 755 (CA755, Bagg-Jackson, Adenocarcinoma)	Mammary Adenocarcinoma	Solid, Ascites or Brei	C57BL	
ADJ-PC-6	Plasmacytoma	Solid or Ascites	BALB/c	
ASB XIV	Pulmonary Squamous Cell Carcinoma	Solid	BALB/c	MVM
AT (Clone Y <sub>1</sub> )	Adrenal	Solid	LAF <sub>1</sub>	
AtT/20	Anterior Pituitary	Solid	LAF <sub>1</sub>	
B16	Melanoma	Solid	C57BL/6	Also see Jax tumors
BL12 Sensitive	Lymphosarcoma	Solid	C57BL/Ka	
BL12/Hc Ra	Lymphosarcoma	Solid	C57BL/Ka	Resistant to cortisone
BW7756	Hepatoma	Solid	C57L/J	See Jax tumors
BW8685	Pituitary	Solid	C57BR/Cdj	See Jax tumors
BW8883	Pituitary	Solid	C57L/J	See Jax tumors
BW10232	Mammary Adenocarcinoma	Solid	C57BL/6J	See Jax tumors
C3HBA	Mammary Adenocarcinoma	Solid	C3H/An	See Jax tumors
C58/J Spontaneous	Leukemia	Spleen Brei	C58	
C95 Spleen/R				See L1210/C95
C1498	Myelogenous Leukemia	Solid	C57BL/6	
C4461	Lung Adenocarcinoma	Solid	A/He	
CA07/A	Colon Adenocarcinoma	Solid	BALB/c	
CA36/Ara C (NSC-63878)	Colon Adenocarcinoma	Solid	BALB/c	
CA51	Colon Adenocarcinoma	Solid	BALB/c	
CaD1	Mammary Adenocarcinoma	Solid	DBA/1J	See Jax tumors
CaD2	Mammary Adenocarcinoma	Solid	DBA/2	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
CCO/1923	Hemangiosarcoma	Solid	B6C3F1	
CE1460 MACA	Mammary Adenocarcinoma	Solid	CE	
CH	Mammary Adenocarcinoma	Solid	Nude C3H	
Cloudman Melanoma	Melanoma	Solid	DBA/1J	See Jax S91
Colon 26	Carcinoma	Solid	BALB/c	
Colon 38	Carcinoma	Solid	C57BL/6	
Crocker Sarcoma				See S180
D <sub>1</sub> T <sub>10</sub>				See LSTRA/DTIC
DBA/2 Spontaneous Tumor M114	Mammary Adenocarcinoma	Solid	DBA/2	
dbrB	Anaplastic Carcinoma	Solid	DBA/1J	See Jax tumors
Egg/Mouse Leukemia	Lymphocytic Leukemia	Ascites	DBA/2, Truslow Egg	
Ehrlich Ascites	Mammary Adenocarcinoma	Solid or Ascites	Various	Several lines
Ehrlich Ascites/6-TG (NSC-752)	Mammary Adenocarcinoma	Ascites	Swiss	Resistant to 6-Thioguanine
Ehrlich Ascites, Tetraploid	Mammary Adenocarcinoma	Ascites	Swiss	
EL-4 Male	Lymphoma	Solid, Spleen C57BL/6 Fragments & Ascites		
E Male Gross	Leukemia	Spleen Homogenate	C57BL/6	
EMT-6	Mammary Adenocarcinoma	Solid	BALB/c	
Ependyblastoma (Zimmerman)	Ependyblastoma	Solid	C57BL/6	
FB SAR (A)	Fibrosarcoma	Solid	C3H	
FB SAR (B)	Fibrosarcoma	Solid	C3H	
FCB (C)	Transitional Cell Carcinoma of Bladder	Solid	C57BL/6	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Friend Virus Leukemia (FV01)	Reticulum Cell Sarcoma	Solid or Spleen Homogenate	DBA/2	
Furth Tumor				See Carcinoma 1025
Glioma 26	Glioma	Solid	C57BL/6	
Glioma 261	Glioma	Solid	C57BL/6	
Gross Leukemia	Leukemia	Solid	C3H	
Gross Mammary Adenocarcinoma	Mammary Adenocarcinoma	Solid	DBA/2	
Hageman Mastocytoma				See P815
Harding-Passey	Melanoma	Solid	BALB/c	Melanotic and amelanotic types
Hauschka Ascites Tumor	Unknown	Ascites	A/He	
HE10734	Osteogenic Sarcoma	Solid	C3H	
HE10734/FR	Osteogenic Sarcoma	Solid	C3H	
Hepatoma 129 (HE129)	Hepatoma	Solid	C3H or Hybrid	
Hepatoma 134 (HE134, Shear Hepatoma 134)	Hepatoma	Ascites	C3H	
HP	Amelanotic Melanoma	Solid	BALB/cJ	See Jax tumors
H6	Hepatoma	Solid	A/J	See Jax tumors
H2712	Mammary Adenocarcinoma	Solid	C3H/HeJ	See Jax tumors
J-30237	Unknown	Ascites	C3H	
Klein Tumor (TA3)	Mammary Adenocarcinoma	Ascites	A/He or CAF <sub>1</sub>	Several lines
Krebs Ascites Carcinoma	Carcinoma of Inguinal Region	Ascites	C3H or CDBA	
Krebs 2 Carcinoma	Carcinoma of Inguinal Region	Ascites	C3H	
L1210	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	
L1210/TSC (NSC-729)	Lymphoid Leukemia	Ascites	DBA/2	Resistant to Thio-semicarbazone

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
L1210/MTX (NSC-740)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	Treated
L1210/6MP (NSC-755)	Lymphoid Leukemia	Ascites	DBA or Hybrid	Several lines
L1210/L-PAM (NSC-8806)	Lymphoid Leukemia	Ascites	DBA/2 or BDF <sub>1</sub>	Treated
L1210/NSC-19622	Lymphoid Leukemia	Ascites	DBA/2	
L1210/5FU (NSC-19893)	Lymphoid Leukemia	Ascites	BDF <sub>1</sub>	
L1210/CTX (NSC-26271)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	
L1210/DF8 (NSC-29630)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or CDBA	Resistant to dichloromethotrexate
L1210/HU (NSC-32065)	Lymphoid Leukemia	Ascites	DBA/2	
L1210/MeGAG (NSC-32946)	Lymphoid Leukemia	Ascites or Spleen Homogenate	CDF <sub>1</sub>	
L1210/NSC-38280	Lymphoid Leukemia	Ascites	CDF <sub>1</sub>	
L1210/DTIC (NSC-45388)	Lymphoid Leukemia	Ascites or Solid	DBA/2 or CDBA	Untreated and treated lines
L1210/TIC (NSC-60339)	Lymphoid Leukemia	Spleen Homogenate	CDBA	Untreated and treated lines
L1210/Ara-C (NSC-63878)	Lymphoid Leukemia	Ascites or Spleen Homogenate	DBA/2 or Hybrid	Untreated and treated lines
L1210/cis-DDP (NSC-119875)	Lymphoid Leukemia	Ascites	DBA/2	Treated
L1210/Anhydro-Ara C (NSC-145668)	Lymphoid Leukemia	Ascites	DBA/2 or Hybrid	Untreated and treated lines
L1210/Ftorafur (NSC-148958)	Lymphoid Leukemia	Ascites	DBA/2 or BDF <sub>1</sub>	Untreated and treated lines
L1210/BCNU (NSC-409962)	Lymphoid Leukemia	Ascites	DBA/2 or Hybrid	Untreated and treated lines
L1210/C95	Lymphoid Leukemia	Ascites or Spleen Brei	CDBA	CTX, MTX, MP resistant

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
L1210 FR3 DCM/R 100a	Lymphoid Leukemia	Spleen Brei	CDBA	
L1210/FR8/DCM	Lymphoid Leukemia	Spleen Brei	CDF <sub>1</sub>	
L1210/FR8 (Folate Reductase)	Lymphoid Leukemia	Spleen Brei	CDF <sub>1</sub>	
L1210/M-773	Lymphoid Leukemia	Ascites	DBA/2	Treated
L1210/6MP/6TG	Lymphoid Leukemia	Ascites	CDF <sub>1</sub>	Untreated and treated lines
L1210 variants				See PR <sub>1</sub> C <sub>1</sub> T <sub>5</sub> /NSC-45388, PR <sub>1</sub> SE <sub>1</sub> T <sub>5</sub> and PR <sub>1</sub> SE <sub>1</sub> T <sub>5</sub> /NSC-45388
L4946	Lymphocytic Leukemia	Solid	AKR	
L5178Y	Leukemia	Ascites	DBA/2 or Hybrid	Several lines
L18464	Lymphoma	Solid	C57BL/6	
LAF <sub>1</sub>	Adrenal Cortical Adenocarcinoma	Solid	LAF <sub>1</sub> /J	
LC-12	Pulmonary Squamous Cell Carcinoma	Solid	BALB/c	
LLC-Luc-GFP (LL-LUC-POL2)	Lung Squamous Cell Carcinoma	Solid	C57BL/6	Grown in mice only, never in tissue culture
Lewis Lung	Carcinoma	Solid	C57BL	
Lewis Lung/PALA (NSC-224131)	Carcinoma	Solid	C57BL/6	
Lewis Sarcoma T241	Pleiomorphic Cell Sarcoma	Solid	C57BL	
LPC-1	Plasmacytoma	Solid or Ascites	BALB/c	
LS402AX	Teratosarcoma	Solid	C57BL/6 and 129	
LSTRA	Lymphosarcoma	Ascites	BALB/c	Several lines
LSTRA/DTIC (NSC-45388)	Lymphosarcoma	Ascites	BALB/c	Untreated and treated lines
M4898	Lung Adenocarcinoma	Solid	BALB/c	
M5076	Reticulum Cell Sarcoma	Solid or Ascites	C57BL/6	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
M5076/L-PAM (NSC-8806)	Reticulum Cell Sarcoma	Solid	C57BL/6	Treated
M5076/HMM (NSC-13875)	Reticulum Cell Sarcoma	Solid	C57BL/6	Treated
M5076/cis-DDP (NSC-119875)	Reticulum Cell Sarcoma	Solid	C57BL/6	Treated
M5480	Testicular Carcinoma (Seminoma)	Solid	C57BL/6	
MA13C	Mammary Adenocarcinoma	Solid	C3H	
MA16C	Mammary Adenocarcinoma	Solid	C3H	
MA387	Fusiform Cell Sarcoma	Solid	AKR	
Madison Lung (TA109)	Carcinoma	Solid	BALB/c	
MC-5	Mammary Adenocarcinoma	Spleen	BALB/c	
MC-6 Female	Mammary Adenocarcinoma	Ascites	BALB/c	
MC-11	Mammary Adenocarcinoma	Spleen Homogenate	BALB/c	
MCS-1	Mammary Adenocarcinoma	Solid or Spleen Homogenate	BALB/c	
Mecca (ME61, MLS)	Lymphosarcoma	Solid or Ascites	C3H or AKR	
METH-A	Sarcoma	Ascites	BALB/c	
MLS				See Mecca
Moloney Sarcoma (SV-122-TR4)	Sarcoma	Solid	BALB/c	
MOPC-4	Plasmacytoma	Solid or Ascites	BALB/c	
MOPC-17	Plasmacytoma	Solid	BALB/c	
MOPC-21	Plasmacytoma	Solid or Ascites	BALB/c	
MOPC-28	Plasmacytoma	Solid	BALB/c	
MOPC-30	Plasmacytoma	Solid	BALB/c	
MOPC-31	Plasmacytoma	Solid	BALB/c	
MOPC-41	Plasmacytoma	Solid	BALB/c	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
MOPC-46	Plasmacytoma	Solid	BALB/c	
MOPC-47	Plasmacytoma	Solid	BALB/c	
MOPC-48	Plasmacytoma	Solid	BALB/c	
MOPC-49	Plasmacytoma	Solid	BALB/c	
MOPC-51	Plasmacytoma	Solid	BALB/c	
MOPC-61	Plasmacytoma	Solid	BALB/c	
MOPC-63	Plasmacytoma	Solid	BALB/c	
MOPC-67	Plasmacytoma	Solid	BALB/c	
MOPC-69	Plasmacytoma	Solid	BALB/c	
MOPC-70	Plasmacytoma	Solid	BALB/c	
MOPC-78	Plasmacytoma	Solid	BALB/c	
MOPC-88	Plasmacytoma	Solid	BALB/c	
MOPC-91	Plasmacytoma	Spleen Homogenate	BALB/c	
MOPC-96	Plasmacytoma	Solid	BALB/c	
MOPC-99	Plasmacytoma	Solid	BALB/c	
MOPC-104	Plasmacytoma	Solid	BALB/c	
MOPC-112	Plasmacytoma	Solid	BALB/c	
MOPC-113	Plasmacytoma	Solid	BALB/c	
MOPC-114	Plasmacytoma	Solid	BALB/c	
MOPC-116	Plasmacytoma	Solid	BALB/c	
MOPC-118	Plasmacytoma	Solid	BALB/c	
MOPC-121	Plasmacytoma	Solid	BALB/c	
MOPC-123	Plasmacytoma	Solid	BALB/c	
MOPC-129	Plasmacytoma	Solid	BALB/c	
MOPC-132	Plasmacytoma	Solid	BALB/c	
MOPC-140	Plasmacytoma	Solid	BALB/c	
MOPC-141	Plasmacytoma	Solid	BALB/c	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
MOPC-157	Plasmacytoma	Solid	BALB/c	
MOPC-172	Plasmacytoma	Solid	BALB/c	
MOPC-173	Plasmacytoma	Solid	BALB/c	
MOPC-209	Plasmacytoma	Solid	BALB/c	
MPC-1	Plasmacytoma	Solid or Ascites	BALB/c	
MPC-2	Plasmacytoma	Solid or Ascites	BALB/c	
MPC-15	Plasmacytoma	Solid	BALB/c	
MPC-25	Plasmacytoma	Solid	BALB/c	
MPC-26	Plasmacytoma	Solid	BALB/c	
MPC-31	Plasmacytoma	Solid	BALB/c	
MPC-36	Plasmacytoma	Solid	BALB/c	
MPC-37	Plasmacytoma	Solid	BALB/c	
MPC-40	Plasmacytoma	Solid	BALB/c	
MPC-42	Plasmacytoma	Solid	BALB/c	
MPC-44	Plasmacytoma	Solid or Ascites	BALB/c	
MPC-48	Plasmacytoma	Solid	BALB/c	
MPC-49	Plasmacytoma	Solid	BALB/c	
MPC-59	Plasmacytoma	Solid	BALB/c	
MPC-60	Plasmacytoma	Solid	BALB/c	
MPC-63	Plasmacytoma	Solid	BALB/c	
MPC-64	Plasmacytoma	Solid	BALB/c	
MPC-67	Plasmacytoma	Solid	BALB/c	
MPC-73	Plasmacytoma	Solid	BALB/c	
MPC-H	Plasmacytoma	Solid	BALB/c	
MST	Mast Cell	Solid	LAF <sub>1</sub>	
MS-2	Sarcoma	Solid	BALB/c	
MXT	Mammary Ductal Papillary Carcinoma	Solid	BDF <sub>1</sub>	Estrogen Responsive
NK-Lymphoma	Lymphoma	Ascites	C57BL/6	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Nettesheim Lung (LePage Clone KLN205)	Squamous Cell Lung Carcinoma	Solid	DBA/2 or Hybrid	
P288	Lymphocytic Leukemia	Solid or Ascites	DBA/2 or CDBA	
P288/MTX (NSC-740)	Lymphocytic Leukemia	Ascites	DBA/2 or BDF <sub>1</sub>	
P388	Lymphocytic Leukemia	Ascites	DBA/2 or CDBA	
P388/MTX (NSC-740)	Lymphocytic Leukemia	Ascites	DBA/2	Treated
P388/ActinomycinD (NSC-3053)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/DON (NSC-7365)	Lymphocytic Leukemia	Ascites	DBA/2	Treated
P388/L-PAM (NSC-8806)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Treated
P388/5FU (NSC-19893)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Treated
P388/CPA (NSC-26271)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Treated
P388/Ara-C (NSC-63878)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	
P388/VCR (NSC-67574)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Untreated and treated lines
P388/Daunomycin (NSC-82151)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/5-Azacytidine (NSC-102816)	Lymphocytic Leukemia	Ascites	DBA/2	Treated
P388/ADR (NSC-123127)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Treated
P388/L-Alanosine (NSC-153353)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Acivicin (NSC-163501)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Amsacrine (NSC-249992)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Mitoxantrone (NSC-301739)	Lymphocytic Leukemia	Ascites	DBA/2	
P388/Ara-A + 2'dcF (NSC-404241 + NSC-218321)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Treated

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
P388/BCNU (NSC-409962)	Lymphocytic Leukemia	Ascites	BDF <sub>1</sub>	Treated
P815 (Hageman Mastocytoma)	Mast Cell Leukemia	Ascites	DBA/2 or Hybrid	
P815/VLB (NSC-49842)	Mast Cell Leukemia	Ascites	DBA/2 or BDF <sub>1</sub>	
P1534	Lymphocytic Leukemia	Spleen Homogenate or Ascites	DBA/2	Several lines
P1798	Lymphosarcoma	Solid or Ascites	BALB/c	
P1798/CR-JS	Lymphoma	Solid	BALB/c	Glucocorticoid resistant, treated
P1798/CS-JS	Lymphoma	Solid	BALB/c	Glucocorticoid sensitive
PAN 02	Pancreas	Solid	C57BL/6	
PAN 03	Pancreas	Solid	C57BL/6	
PR <sub>1</sub> C <sub>1</sub> T <sub>5</sub> /NSC-45388	Lymphoid Leukemia	Ascites	CDF <sub>1</sub>	L1210 variant; treated
PR <sub>1</sub> SE <sub>1</sub> T <sub>5</sub>	Lymphoid Leukemia	Ascites	CDF <sub>1</sub>	L1210 variant
PR <sub>1</sub> SE <sub>1</sub> T <sub>5</sub> /NSC-45388	Lymphoid Leukemia	Ascites Homo- genate	CDF <sub>1</sub>	L1210 variant; treated
R-26	Unknown	Ascites	CDF <sub>1</sub>	
R-46	Unknown	Ascites	CDF <sub>1</sub>	
R-53	Unknown	Ascites	CDF <sub>1</sub>	
R-74	Unknown	Ascites	CDF <sub>1</sub>	
RBL-5 (Rauscher Virus Induced Transplantable Tumor-5)	Leukemia	Ascites	C57BL/6	
RC-2	Renal Adenocarcinoma	Ascites	CDF <sub>1</sub>	
Reif-Allen Tumor	Thymoma	Ascites	AKR	
RPC-5	Plasmacytoma	Solid	BALB/c	
RPC-9	Plasmacytoma	Solid or Ascites	BALB/c	
RPC-20	Plasmacytoma	Solid or Ascites	BALB/c	
S37	Pleomorphic Cell Sarcoma	Ascites	BALB/c, Nonspecific	See Jax tumors

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
S180 (Crocker, S III)	Pleomorphic Cell Sarcoma	Solid or Ascites	BALB/c, Swiss or hybrids	See Jax tumors
Sa 1	Spindle Cell Sarcoma	Solid	A/J	See Jax tumors
Sa D2	Fibrosarcoma	Solid	DBA/2J	See Jax tumors
Shear Hepatoma 134				See Hepatoma 134
SJL/JW	Reticulum Cell Sarcoma	Spleen Homogenate	SJL/JW	
Spontaneous Adrenal	Adrenal	Solid	CE/J	
Spontaneous DBA/2 Mammary	Mammary Adenocarcinoma	Solid	DBA/2	
Spontaneous Mammary	Mammary Adenocarcinoma	Solid	DBA/2	
SV-122-TR4				See Moloney Sarcoma
TA3				See Klein tumor
TA109				See Madison Lung
T1699	Mammary Adenocarcinoma	Solid	DBA/2J	See Jax tumors
T1703	Mammary Adenocarcinoma	Solid	DBA/1J	See Jax tumors
X5563	Unknown	Solid	C3H/He	
YPC-1	Plasmacytoma	Ascites	BALB/c	
Zimmerman Ependymoblastoma				See Ependymoblastoma
6C3HED (Gardner)	Lymphosarcoma	Ascites	C3H	Several lines. See Jax tumors
6C3HED/AR Res.	Lymphosarcoma	Spleen Homogenate	C3H	
102A	Unknown	Ascites	CDF <sub>1</sub>	
1247	Mammary Adenocarcinoma	Solid	BALB/c	
36230 TLT	Hemangio-endothelioma	Solid	C57BL/6J	
36257 TTT	Fibrosarcoma	Solid	BALB/cAnN	

<b>SPECIES: MOUSE</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
38290 TTT	Fibrosarcoma	Solid	BALB/cAnN	
42021 TCT	Hemangio- endothelioma	Solid	BALB/cAnN	
42022 TST	Hemangio- endothelioma	Solid	BALB/cAnN	
42052 TST	Hemangio- endothelioma	Solid	C57BL/6J	
42076 TST	Hemangio- endothelioma	Solid	C57BL/6J	
44316 TST	Hemangio- endothelioma	Solid	BALB/cAnN	
44316 LTST	Hemangio- endothelioma	Solid	BALB/cAnN	
44347 TST	Hemangio- endothelioma	Solid	BALB/cAnN	
46362 TTT	Fibrosarcoma	Solid	C57BL/6J	
46363 TTT	Fibrosarcoma	Solid	BALB/cAnN	
70429	Plasmacytoma	Ascites	C3H	
70429/Azaserine (NSC-3425)	Plasmacytoma	Ascites	C3HF/LW	
91632	Reticulum Cell Sarcoma	Solid	C57BL/Kaplan	

**MOUSE TUMORS FROM THE JACKSON LABORATORY**

**MOUSE TUMORS FROM THE JACKSON LABORATORY IN CRYOPRESERVATION IN THE DCTD TUMOR REPOSITORY**

<b>Tumor Designation</b>	<b>Tumor Type</b>	<b>Host Strain</b>	<b>Transplantation Frequency (days)</b>	<b>Host Survival (days)</b>	<b>Lag Time* (days)</b>	<b>Strain of Origin</b>	<b>Sex of Origin</b>	<b>MRI Bank #</b>	<b>MAP Test <sup>+</sup></b>
dbrB	Anaplastic Carcinoma	DBA/1J	7	7-9	5-7	DBA		J-730	LDH+
SaD2	Fibrosarcoma	DBA/2J	10	19-12	8-15	DBA/2J		J-765	LDH+
H6	Hepatoma	A/J	10-14	14-44	7-9	A/J		J-750	LDH+
BW7756	Hepatoma	C57L/J	14	13-31	12-16	C57L/J		J-748	LDH+
6C3HED (GL-1)	Lymphosarcoma	C3H/HeJ	7	7-9	16	C3h	--	J-744	LDH+
BW10232	Mammary Adenocarcinoma	C57BL/6J	10	23-30	11	C57BL/6J		J-762	LDH+
C3HBA	Mammary Adenocarcinoma	C3H/HeJ	10	39-77	11-16	C3H/An		H-758	LDH+
H2712	Mammary Adenocarcinoma	C3H/HeJ	7	14-27	11-19	C3H/HeHu		J-731	LDH+
CaD1	Mammary Adenocarcinoma	DBA/1J	10	25-43	9-17	DBA/1J		J-742	LDH+
T1703	Mammary Adenocarcinoma	DBA/1J	10	47-74	9-12	DBA/1Hu		J-737	LDH+
T1699	Mammary Adenocarcinoma	DBA/2J	10	19-39	8-10	DBA/2J		J-736	LDH+
HP	Melanoma (amelanotic)	BALB/cJ	14	28-77	19-23	nonlabred	--	J-746	LDH+
B16	Melanoma (amelanotic)	C57BL/6J	10	24-44	15-21	C57BL/6J	--	J-753	LDH+
S91	Melanoma (melanotic)	DBA/1J	17-21	49-98	16-18	DBA (Snell)	--	J-749	LDH+
C1498	Myeloid Leukemia	C57BL/6J	7	9-16	7-9	C57BL	--	J-738	LDH+
BW8883	Pituitary	C57L/J	60	182-273	65-73	C57L/J	--	J-756	LDH+

Tumor Designation	Tumor Type	Host Strain	Transplantation Frequency (days)	Host Survival (days)	Lag Time* (days)	Strain of Origin	Sex of Origin	MRI Bank #	MAP Test <sup>†</sup>
BW8685	Pituitary	C57BR/dcJ	90-120	210-238	395	C57BR/cdj		J-794	LDH+
S180	Pleomorphic Sarcoma	BALB/cJ	10	21-31	9-11	"white" mouse		J-757	LDH+
S37	Pleomorphic Sarcoma	DBA/1J	7	21-28	6-13	"stock" mouse		J-759	LDH+
C1300	Round cell (Neuroblastoma?)	A/J	10	19-32	14-21	A albino	--	J-734	LDH+ MHV+
Sal	Spindle-cell Sarcoma	A/J	7	9-15	7-9	A albino	--	J-733	LDH+

\*Length of lag phase before measurable tumor growth (5 mm average diameter) is evident in the first passage post thaw.

<sup>†</sup>MAP Test - Murine Antigen Profile for 12 common viruses: PVH, Rco 3, Sendai, GDVII, K, Polyoma, MVH, MAB, MHV, LCM, Ectromelia, LDH. Only positive results are listed.

Adapted from Jax Notes, No. 424, December 1975.

## **RABBIT TUMORS**

<b>SPECIES: RABBIT</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Brown-Pearce	Carcinoma (Epithelioma)	Solid	New Zealand White or Dutch	
VX-2 (V2)	Skin Carcinoma	Solid	New Zealand White or Dutch	

## **RAT TUMORS**

<b>SPECIES: RAT</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
AA Ascites	Spontaneous Ascites	Ascites	Wistar	
ATC 64	Thyroid Carcinoma	Solid	Fischer 344	
9A Ascites	Spontaneous Ascites	Ascites	Inbred PA	
A546 (DMBZ Attenuated)	Unknown	Solid	Fischer 344	
A920 (Tetramin Attenuated Resistant)	Unknown	Solid	Fischer 344	
A1011	Unknown	Solid	Fischer 344	
A1131-AR	Unknown	Solid	Fischer 344	
A1138-AL	Unknown	Solid	Fischer 344	
A1140-CL-10	Unknown	Solid	Fischer 344	
BT/M520	Fibrosarcoma	Solid	Marshall 520	
Carcinosarcoma	Carcinosarcoma (skin) (18-day embryos)	Solid	Sprague-Dawley Derived Holtzman	
CA 20948	Pancreatic Acinar Carcinoma	Solid	Wistar	
CCO 1865	Mesothelioma	Solid	Fischer 344	
CSE	Fibrosarcoma	Solid	Fischer 344	H-1
DD81-23	T cell lymphoma	Mince	Fischer 344	
DL Wells-17	T cell lymphoma	Mince	Fischer 344	
DMBA	Mammary Adenocarcinoma	Solid	Fischer 344	Several lines
DSL62-38	Pancreatic Tumor	Solid	Wistar Lewis	
Dunning Leukemia	Atypical Monocytic Leukemia	Solid or Ascites	Fischer 344	H-1 H-1, KRV
Dunning Leukemia/ NSC-755 (6-MP)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-3088 (chlor- ambucil)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-10107 (nitromin)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-13875 (HMM)	Atypical Monocytic Leukemia	Solid	Fischer 344	

<b>SPECIES: RAT</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Dunning Leukemia/ NSC-17261 (benzo- quinone)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-23892 (dimethyl- benzimidazole)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-26980 (mitomycin C)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-29422 (thio- guanosine)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-45059 (o-acetyl- tetramin)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Dunning Leukemia/ NSC-51845 (cyclo- hexylamine)	Atypical Monocytic Leukemia	Solid	Fischer 344	
Flexner-Jobling	Seminal Vesicle Adenocarcinoma	Solid	Nonspecific, Sprague- Dawley or Wistar	
Fran Tumor	Ovarian Carcinoma	Ascites	Sprague-Dawley	
GBT/W	Glial Tumor	Solid	Wistar	
HB Lynch-Fibroma 522	Fibroma	Solid	Fischer 344	
Hepatoma NK				See Novikoff Hepatoma
HMC	Histiocytoma	Solid	Fischer 344	
H-372	Leydig	Solid	Fischer 344	
H-540	Leydig	Solid	Fischer 344	
Iglesias	Ovarian Carcinoma	Solid	ACI	
IRS 9802	Spindle Cell Sarcoma	Solid	Fischer 344	
LC-18	Hepatoma	Solid	Fischer 344	
Lymphoma 8	Lymphoma	Solid, Spleen Homogenate, Whole Blood	Lewis	
L.T.W. (Furth)	Leydig	Solid	Wistar	
MAMF2-TC	Fibrosarcoma	Solid	Fischer 344	
MET 149-2	Adenocarcinoma	Solid	Fischer 344	

<b>SPECIES: RAT</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
Moore Sarcoma #1	Sarcoma	Solid	Wistar	
Morris Hepatomas	Hepatoma	Solid	Buffalo	
16 Morris	Hepatoma	Solid	Buffalo	
20 Morris	Hepatoma	Solid	Buffalo	
44 Morris	Hepatoma	Solid	Buffalo	
3924A	Hepatoma	Solid	ACI	
5123 Morris	Hepatoma	Solid	Buffalo	
7777 Morris	Hepatoma	Solid	Buffalo	
7800 Morris	Hepatoma	Solid	Buffalo	
8999 Morris	Hepatoma	Solid	Buffalo	
9618A Morris	Hepatoma	Solid	Buffalo	
MNU-Buffalo	Mammary Carcinoma	Solid	Buffalo	Several lines
MtT	Anterior Pituitary	Solid	Fischer, Wistar	Several lines
MT/W9	Mammary Adenocarcinoma	Solid	Wistar	Several lines
MT/W449	Mammary Adenocarcinoma	Solid	Wistar	Several lines
Murphy-Sturm Lymphosarcoma (MSL)	Lymphosarcoma	Solid	CRL, Wistar, Fischer 344, Sprague-Dawley	
NBW-37	T cell lymphoma	Mince	Fischer 344	
Novikoff Hepatoma (Hepatoma NK)	Hepatoma	Solid or Ascites	Random bred albino	(Sprague-Dawley weanlings)
NS104	Rhabdomyosarcoma	Solid	Fischer 344	
OR-16-3	Thymus Tumor	Solid	Fischer 344	
R35	Mammary Adenocarcinoma	Solid	Holtzman	
R3259	Giant Cell Sarcoma	Solid	Fischer 344	
Rice D6	Leydig	Solid	Fischer 344	
Rice 500	Leydig	Solid	Fischer 344	
Riejoel	Thyroid Adenocarcinoma	Solid	Fischer 344	

<b>SPECIES: RAT</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
RNC 259	Pheochromocytoma	Solid	NEDH	
RNC 288	Insulinoma	Solid	NEDH	
RNK-16	LGL Leukemia	Solid or Spleen Homogenate	Fischer 344	
R3149	Leukemia	Solid	Fischer 344	
R3230AC	Mammary Adenocarcinoma	Solid	Fischer 344	
R3327	Prostate	Solid	Copenhagen 2331	
R3327 (Pap)	Prostate	Solid	Copenhagen 2331	
3M2N	Mammary Squamous Cell Carcinoma	Solid	Fischer 344	
Shay Leukemia	Myelogenous Leukemia	Solid	Sprague-Dawley	
SMT-2A	Mammary Carcinoma	Solid	Fischer 344	
Swarm	Chondrosarcoma	Solid	Sprague-Dawley	
TR.CLXXXVIII	Melanoma	Solid	ACI	
TR.DCCXLIII	Pituitary	Solid	ACI	
Walker 256	Carcinosarcoma	Solid or Ascites	Sprague-Dawley	
Yoshida Hepatoma	Hepatoma	Ascites	Sprague-Dawley	
Yoshida Sarcoma	Sarcoma	Solid or Ascites	Holtzman, S-D	
68-2	Alveolar/Bronchiolar Carcinoma	Solid	Fischer 344	
13762	Mammary	Solid or Ascites	Fischer 344	Several lines
13762-FS	Fibrosarcoma	Solid	Fischer 344	
23 Methapyrilene	Hepatocellular Carcinoma	Solid	Fischer 344	
29 Methapyrilene	Hepatocellular Carcinoma	Solid	Fischer 344	
33 Methapyrilene	Hepatocellular Carcinoma	Solid	Fischer 344	
2982	Olfactory Neuroblastoma	Solid	Fischer 344	
11095	Prostate	Solid	Fischer 344	

**RAT TUMORS FROM DR. ROBERT NOBLE (ENDOCRINE-RESPONSIVE)**

SPECIES: RAT (tumors received from Dr. Robert Noble)

Information concerning the endocrinologic characteristics of the various tumor systems indicated in the "comments" is that supplied by Dr. Noble.

<b>SPECIES: RAT (tumors received from Dr. Robert Noble)</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
1 Cvx-34A(1)	Cervical Carcinoma	Solid	NB	
1 Cvx-44Z	Cervical Carcinoma	Solid	NB	Estrogen dependent
1 Lym-206	Lymphoma	Solid	NB	Hormone stimulated
1 Lym-209(A)	Lymphoma	Solid	NB	Hormone stimulated, VLB sensitive
1 Lym-214	Lymphosarcoma	Solid	NB	Hormone stimulated
1 Og-3	Osteogenic Sarcoma	Solid	NB	
1 Pan-14Ax(1)	Adenocarcinoma	Solid	NB	Hormone stimulated
1 Sal-23(2)	Salivary Gland, Secretory Tumor	Solid	NB	Estrogen dependent
1 Tes-13E	Leydig Cell Carcinoma	Solid	NB	Estrogen dependent
1 TES-15E	Leydig Cell Carcinoma	Solid	NB	Estrogen dependent
Kid-27B	Kidney Adenocarcinoma	Solid	NB	
2 Lym-11(a)	Metaplastic, Adeno- carcinoma Fibroblast Overgrowth	Solid	NB	Estrogen dependent
2-Pan-6A	Pituitary Adenoma	Solid	NB	Hormone stimulated
2-Pr-7A	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-9F	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-12	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-112Bx(1)	Prostatic Carcinoma, Scirrhus	Solid	NB	
2 Pr-114B	Prostatic Adenocarcinoma	Solid	NB	Estrogen dependent
2 Pr-121D(1)	Prostatic Carcinoma, Secretory	Solid	NB	Androgen dependent
2 Pr-121D(1)/R	Prostatic Carcinoma	Solid	NB	Resistant to testosterone
2 Sk-103	Melanoma	Solid	NB	
2 Ut-10(5)	Fibroma	Solid	NB	Estrogen dependent
3 Kid-13	Kidney Adenocarcinoma	Solid	NB	
3 Lym-19	Lymphosarcoma	Solid	NB	
4 Pan-6	Adenocarcinoma	Solid	NB	

<b>SPECIES: RAT (tumors received from Dr. Robert Noble)</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
4 Sk-3A(3)Z	Squamous Cell Carcinoma	Solid	NB	
4 Ut	Hemangiosarcoma	Solid	NB	
4 Ut-6(2)	Fibrosarcoma	Solid	NB	Estrogen dependent or hormone stimulated
5 Pan-7	Undifferentiated Pancreatic Carcinoma	Solid	NB	
5 Sal	Undifferentiated Carcinoma	Solid	NB	
5 Sk-3	Melanoma	Solid	NB	
5 Ut-2	Uterine Adenocarcinoma	Solid	NB	Estrogen dependent (?)
6 Pan-4	Undifferentiated Pancreatic Carcinoma	Solid	NB	
7 Ut-13	Endometrial Adenocarcinoma	Solid	NB	
8 Lym-9(1)	Lymphosarcoma	Solid	NB	VLB resistant
8 Lym-108(1)	Lymphatic Leukemia	Solid	NB	VLB resistant
9 Lym-23	Lymphosarcoma	Solid	NB	
10 Lym-4	Negative Spleen	Solid	NB	
11 Lym-9	Lymphosarcoma	Solid	NB	
13 Pr-5	Prostatic Carcinoma, Undifferentiated	Solid	NB	Estrogen pellet implant required
14 Lym-5	Lymphosarcoma stimulated	Solid	NB	Hormone
14 Pr-5	Prostatic Carcinoma	Solid	NB	
15 Pr-2	Prostatic Adenocarcinoma	Solid	NB	
16 Pr-3	Prostatic Adenocarcinoma	Solid	NB	
17 Lym-4	Lymphosarcoma implant required	Solid	NB	Estrogen pellet
17 Lym-5	Leukemia	Solid	NB	
18 Lym-6	Lymphosarcoma	Solid	NB	Estrogen dependent
19 Lym-3	Lymphosarcoma	Solid	NB	Estrogen dependent
19 Pr-19	Prostatic Fibroadenoma	Solid	NB	
20 Pr-1	Prostatic Fibroadenoma	Solid	NB	
20 Lym-3	Lymphosarcoma	Solid	NB	Estrogen pellet implant required

<b>SPECIES: RAT (tumors received from Dr. Robert Noble)</b>				
<b>Tumor Designation</b>	<b>Histologic Type</b>	<b>Form</b>	<b>Strain of Origin/ Transplant</b>	<b>Comments</b>
21 Pr-9	Prostatic Carcinoma	Solid	NB	
22 Pr-8	Prostatic Adenocarcinoma	Solid	NB	
23 Pr-7	Prostatic Carcinoma	Solid	NB	
24 Pr-2	Prostatic Carcinoma	Solid	NB	
25 Pr-3	Prostatic Adenocarcinoma	Solid	NB	

***IN VITRO* ESTABLISHED CELL LINES**

<b>HUMAN IN VITRO CELL LINES</b>				
<b>Designation</b>	<b>Tissue of Origin</b>	<b>Histologic Type</b>	<b>Growth Medium</b>	<b>Remarks</b>
ACHN	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Schmid
A2780	Ovary	Adenocarcinoma	RPMI 1640	From Dr. Hamilton
A498	Kidney	Renal Cell Carcinoma	RPMI 1640	ATCC
A549	Lung	Non-small Cell	RPMI 1640	ATCC
A704	Kidney	Renal Cell Carcinoma	RPMI 1640	ATCC
BT-549	Breast	Adenocarcinoma	RPMI 1640	ATCC
CAKI-1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Loveless
CCRF-CEM	Lymph	Leukemia	RPMI 1640	ATCC
CCRF-SB	Lymph	Leukemia	RPMI 1640	ATCC
CHA-59	Bone	Osteosarcoma	RPMI 1640	From Drs. Shoemaker and McLachlan
COLO 205	Colon	Adenocarcinoma	RPMI 1640	ATCC
DMS-114	Lung	Small Cell	RPMI 1640	From Dr. Pettengill
DU-145	Prostate	Carcinoma	RPMI 1640	ATCC
EKVX	Lung	Adenocarcinoma	RPMI 1640	From Dr. Fodstad
HCC-2998	Colon	Adenocarcinoma	RPMI 1640	From Dr. Fidler
HCT-15	Colon	Carcinoma	RPMI 1640	ATCC
HCT-116	Colon	Adenocarcinoma	RPMI 1640	ATCC
HELA	Cervix	Carcinoma		
HOP-18	Lung	Large Cell Carcinoma	RPMI 1640	From Drs. Liu/Casero
HOP-62	Lung	Adenocarcinoma	RPMI 1640	From Drs. Liu/Casero
HOP-92	Lung	Large Cell	RPMI 1640	From Dr. Liu
HL-3		Lymphoma		
HL-4		Lymphoma		
HL-60	Ascites	Pro-myelocytic Leukemia	RPMI 1640	From E. Jensen
H-MESO-1		Mesothelioma	RPMI 1640	
HS 578T	Breast	Adenocarcinoma	RPMI 1640	ATCC
HS 913T	Lung	Mixed Cell	RPMI 1640	ATCC
HT-29	Colon	Adenocarcinoma	RPMI 1640	ATCC
IGR-OV1	Ovary	Adenocarcinoma	RPMI 1640	From Dr. Benard

<b>HUMAN IN VITRO CELL LINES</b>				
<b>Designation</b>	<b>Tissue of Origin</b>	<b>Histologic Type</b>	<b>Growth Medium</b>	<b>Remarks</b>
KB-ADL #12	Oral Cavity	Epidermoid	EMEM	
KM-12	Colon	Adenocarcinoma	RPMI 1640	From Dr. Fidler
KM 20L2	Colon	Adenocarcinoma	RPMI 1640	From Dr. Fidler
K-562	Lymph	Leukemia	RPMI 1640	ATCC
LOVO	Colon	Adenocarcinoma	RPMI 1640	ATCC
LOX IMVI	Lymph Node Metastasis	Amelanotic Melanoma	RPMI 1640	From Dr. Fodstad
LXFL 529**	Lung	Large Cell Carcinoma	RPMI 1640	From Dr. Fiebig**
MALME-3M	Lung Metastasis	Melanoma	RPMI 1640	ATCC
MCF7	Breast	Adenocarcinoma	RPMI 1640	From Dr. Cowan
MDA-MB-231	Breast	Adenocarcinoma	RPMI 1640	From Dr. Moore
MDA-MB-435	Melanoma	Adenocarcinoma	RPMI 1640	From Dr. Steeg
MDA-MB-468	Breast	Adenocarcinoma		
MOLT-4	Lymph	Leukemia	RPMI 1640	ATCC
MX-1	Breast	Carcinoma	RPMI 1640	From Dr. Giovannelli
M14		Amelanotic Melanoma	RPMI 1640	From Dr. Kern
M19-MEL		Amelanotic Melanoma	RPMI 1640	From Dr. Kern
NC-37	Lymphoblast	Normal		
NCI-H23	Lung	Adenocarcinoma	RPMI 1640	From Dr. Gazdar
NCI-H69	Lung	Small Cell Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H82	Lung	Small Cell Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H125	Lung	Adenosquamous Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H226	Lung	Squamous Cell	RPMI 1640	From Dr. Gazdar
NCI-H292	Lung	Adenosquamous Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H322M	Lung	Adenocarcinoma	RPMI 1640	From Dr. Gazdar
NCI-H358M	Lung	Bronchioalveolar Carcinoma	RPMI 1640	From Dr. Gazdar
NCI-H460	Lung	Large Cell	RPMI 1640	From Dr. Gazdar
NCI-H522	Lung	Adenocarcinoma	RPMI 1640	From Dr. Gazdar
NCI/ADR-RES	Ovary	Adenocarcinoma	RPMI 1640	From Dr. Cowan Please see JNCI correspondence on page 64
OV	Ovary			

<b>HUMAN IN VITRO CELL LINES</b>				
<b>Designation</b>	<b>Tissue of Origin</b>	<b>Histologic Type</b>	<b>Growth Medium</b>	<b>Remarks</b>
OVCAR-3	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
OVCAR-4	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
OVCAR-5	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
OVCAR-8	Ovary	Adenocarcinoma	RPMI 1640	From Drs. Ozols and Hamilton
PC-3	Prostate	Carcinoma	RPMI 1640	From Dr. Kaighn
PC-3/M	Prostate	Carcinoma	RPMI 1640	From Dr. Kaighn
RPMI-7951		Melanoma	RPMI 1640	ATCC
RPMI-8226	Lymph	Leukemia	RPMI 1640	ATCC
RXF 393	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fiebig
RXF 631	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fiebig
SF-268	CNS	Glioblastoma	RPMI 1640	From Dr. Rosenblum
SF-295	CNS	Glioblastoma	RPMI 1640	From Dr. Rosenblum
SF-539	CNS	Glioblastoma	RPMI 1640	From Dr. Rosenblum
SHP-77	Lung	Small Cell Carcinoma	RPMI 1640	From Dr. Fisher
SK-OV-3	Ovary	Adenocarcinoma	RPMI 1640	ATCC
SK-MEL-2		Melanoma	RPMI 1640	ATCC
SK-MEL-5		Melanoma	RPMI 1640	ATCC
SK-MEL-28		Melanoma	RPMI 1640	ATCC
SK-MES-1	Lung	Squamous Cell Carcinoma	RPMI 1640	ATCC
SN12A1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12C	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12K1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12L1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SN12S1	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Fidler
SNB-7	CNS	Glioblastoma	RPMI 1640	From Dr. Kornblith
SNB-19	CNS	Glioblastoma- (Same as U251)	RPMI 1640	From Dr. Kornblith
SNB-75	CNS	Glioblastoma	RPMI 1640	From Dr. Kornblith
SNB-78	CNS	Astrocytoma	RPMI 1640	From Dr. Kornblith
SR	Pleural effusion	Lymphoma	RPMI 1640	From Dr. Urba

<b>HUMAN IN VITRO CELL LINES</b>				
<b>Designation</b>	<b>Tissue of Origin</b>	<b>Histologic Type</b>	<b>Growth Medium</b>	<b>Remarks</b>
SW-620	Colon		RPMI 1640	ATCC
T-47D	Breast		RPMI 1640	Not distributed to commercial firms or for commercial purposes
TK-10	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Clayman
UACC-62		Melanoma	RPMI 1640	From Dr. Leibowitz
UACC-257		Melanoma	RPMI 1640	From Dr. Leibowitz
UCSD 242L		Melanoma	RPMI 1640	From Dr. Taetle
UCSD 354L		Melanoma	RPMI 1640	From Dr. Taetle
UO-31	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Linehan
U-251	CNS	Glioblastoma- (Same as SNB-19)	RPMI 1640	From Dr. Bigner
WIDR	Colon	Adenocarcinoma	RPMI 1640	ATCC
XF 498	CNS	Glioblastoma	RPMI 1640	From Dr. Fiebig
786-0	Kidney	Renal Cell Carcinoma	RPMI 1640	From Dr. Williams

<b>NIH LICENSED CELL LINES</b>				
<b>Designation</b>	<b>Tissue of Origin</b>	<b>Histologic Type</b>	<b>Growth Medium</b>	<b>Remarks</b>
293TT	Human Embryonic Kidney	Kidney	DMEM 10% FBS	Schiller/Pang
NCI-H838	Human Lung Adenocarcinoma NSCLC	Adenocarcinoma	RPMI 1640	Gazdar/Minna
NCI-H2887	Human Lung Adenocarcinoma NSCLC	Adenocarcinoma	RPMI 1640	Gazdar/Minna
NCI-H3122	Human Lung Adenocarcinoma NSCLC	Adenocarcinoma	RPMI 1640	Gazdar/Minna
NCI-H3255	Human Lung Adenocarcinoma NSCLC	Adenocarcinoma	ACL-4 + 10%FBS + 1% Glutamine	Gazdar/Minna

NCI ANTI-CANCER CELL LINE PANEL						
Cell Line	Sex	Age	Histology	Comment	Treatment	Source
<b>COLON</b>						
COLO 205	M	70	Adenocarcinoma	Can Res 38: 1345-1355, 1978		
HCC-2998			Carcinoma		N	
HCT-15			Adenocarcinoma	Can Res 39: 1020-1025, 1979		
HCT-116			Carcinoma	Can Res 41: 1761-1756, 1981		
HT29	F	44	Adenocarcinoma, GR III	Human Tumor Cells In Vitro: 115-159, 1975		Primary
KM12			Adenocarcinoma	Can Res 48: 1943-1948, 1988	N	
SW-620	M	51	Adenocarcinoma	Can Res 36: 4562-4569, 1976		Metastasis
<b>CNS</b>						
SF-268	F	24	Anaplastic Astrocytoma	Acta Neuropathol 75: 92-103, 1987		
SF-295	F	67	Glioblastoma-Multiforme	Acta Neuropathol 75: 92-103, 1987		
SF-539				J Neuropathol Exp Neurol 40: 201- 229, 1981		
SNB-19	M	47	Glioblastoma (same as U251)	Cancer 47: 255, 1981	N	
SNB-75	F		Astrocytoma		N	
U251	M	75	Glioblastoma (same as SNB-19)	J Neuropathol Exp Neurol 40: 410-427, 1981		
<b>LEUKEMIA</b>						
CCRF-CEM	M	4	Acute Lymphoblastic Leukemia	Can Res 18: 522-529, 1965		
HL-60(TB)	F	36	Promyelocytic Leukemia	Nature 270: 347-349, 1977		PBL
K-562	F	53	Chronic Myelogenous Leukemia	Blood 45: 321-334, 1975		Pleural Effusion
MOLT-4	M	19	Acute Lymphoblastic Leukemia	JNCI 49: 891-895, 1972		PB
RPMI-8226	M	61	Myeloma	Proc Soc Exp Biol Med 125: 1246-1250, 1967		PB
SR	M	11	Large Cell, Immunoblastic		Y	
<b>LUNG</b>						
A549/ATCC	M	58	Adenocarcinoma	JNCI 51: 1417-1423, 1973		Primary
EKVX	M		Adenocarcinoma			
HOP-62	F	60	Adenocarcinoma		N	
HOP-92	M	62	Large Cell, Undifferentiated		N	
NCI-H23			Adenocarcinoma	Can Res 45: 2913-2923, 1985	N	
NCI-H226			Squamous	Can Res 45: 2913-2923, 1985		

NCI ANTI-CANCER CELL LINE PANEL						
Cell Line	Sex	Age	Histology	Comment	Treatment	Source
<b>LUNG (continued)</b>						
NCI-H322M			Small Cell Bronchioalveolar Carcinoma		N	
NCI-H460	M		Large Cell Carcinoma	Science 246: 491-494, 1989	N	Pleural Effusion
NCI-H522			Adenocarcinoma	Can Res 45: 2913-2923, 1985		
<b>MAMMARY</b>						
MCF7	F	69	Adenocarcinoma	JNCI 51: 1409-1417, 1973	Y	
HS 578T	F	74	Carcinosarcoma	JNCI 58: 1795-1806, 1977		Primary
MDA-MB-231	F	51	Adenocarcinoma	JNCI 53: 661-674, 1974	Y	
MDA-MB-468	F	51	Adenocarcinoma	Cancer Res 40: 3118-3129, 1980		
BT-549	F	72	Papillary Infiltrating Ductal Carcinoma	No Publication		Metastasis
T-47D*	F	54	Infiltrating Ductal Carcinoma	Eur J Cancer 15: 659-670, 1979		*not for commercial use
<b>MELANOMA</b>						
LOX IMVI			Malignant Amelanotic Melanoma	Int J Cancer 41: 442-449, 1988		
M14						
MALME-3M	M	43	Malignant Melanoma	Human Tumor Cells In Vitro, 115-159, 1975		Metastasis
MDA-MB-435	F	31	Adenocarcinoma	Can Res 40: 3118-3129, 1980	N	
SK-MEL-2	M	60	Malignant Melanoma	Human Tumor Cells In Vitro, 115-159, 1975		Metastasis
SK-MEL-5			Malignant Melanoma	PNAS 73: 3278-3282, 1976		Metastasis
SK-MEL-28			Malignant Melanoma	PNAS 73: 3278-3282, 1976		
UACC-62						
UACC-257						
<b>OVARIAN</b>						
IGR-OV1	F	47	Cystadenocarcinoma	Can Res 45: 4970-4979, 1985	N	
NCI/ADR-RES	F		Adenocarcinoma	JNCI 90(11): 6/3/1998		
OVCAR-3	F	60	Adenocarcinoma	Can Res 43: 5379-5389, 1983	Y	Ascites
OVCAR-4	F	42	Adenocarcinoma	Sem Oncol 11: 285-298, 1984	Y	
OVCAR-5	F	67	Adenocarcinoma	Sem Oncol 11: 285-298, 1984	N	
OVCAR-8	F	64	Adenocarcinoma	Sem Oncol 11: 285-298, 1984	Y	
SK-OV-3	F	64	Adenocarcinoma	Human Tumor Cells In Vitro, pp 115-159,	Y	Ascites

<b>NCI ANTI-CANCER CELL LINE PANEL</b>						
<b>Cell Line</b>	<b>Sex</b>	<b>Age</b>	<b>Histology</b>	<b>Comment</b>	<b>Treatment</b>	<b>Source</b>
				1975		
<b>PROSTATE</b>						
DU-145	M	69	Carcinoma	Int J Cancer 21: 274-281, 1978	Y	
PC-3	M	62	Adenocarcinoma	Invest Urol 17: 16-23, 1979	Y	Metastasis
<b>RENAL</b>						
786-O	M	58	Adenocarcinoma	In Vitro 12: 623-627, 1976	N	
A498	F	52	Adenocarcinoma	JNCI 51: 1417-1423, 1973		
ACHN	M	22	Renal Cell Carcinoma	Can Res 42: 4948-4953, 1982	Y	Pleural Effusion
CAKI-1	M	49	Clear Cell Carcinoma	Human Tumor Cells In Vitro, pp. 115-159, 1975	Y	Metastasis
RXF 393	M	54	Poorly Differentiated Hypernephroma	Contrib Oncol 42, 1992	N	
SN12C	M	43	Carcinoma	Can Res 46: 4109-4115, 1986		
TK-10	M	43	Spindle Cell Carcinoma	Can Res 47: 3856-3862, 1987	N	
UO-31			Carcinoma		N	

## CORRESPONDENCE

### Cell Line Designation Change: Multidrug-Resistant Cell Line in the NCI Anticancer Screen

Since 1990, the Developmental Therapeutics Program (DTP) of the National Cancer Institute (NCI) has screened over 60,000 compounds and a larger number of natural product extracts for their capacity to inhibit the growth of 60 different human tumor cell lines (1). These cell lines have been maintained in cryopreservation and in culture, and they have been subjected to strict quality controls, including adventitious agent testing, human isoenzyme analysis, karyology, morphological and immunocytochemical characterization (2), and DNA fingerprinting. One of these cell lines, previously designated as MCF-7/ADR-RES, has been included in the *in vitro* cell line screening panel because of its stable multidrug-resistant (MDR) phenotype (3) characterized by high levels of MDR-1 and P-glycoprotein expression (4,5). Recently, we submitted cell lines from the screening panel for DNA fingerprinting analysis by three different laboratories. Included in the tested cell lines were MCF-7 and MCF-7/ADR-RES. Utilizing restriction fragment length polymorphism (RFLP) testing, CellMark Diagnostics (Germantown, MD) concluded that their DNA fingerprinting data were consistent with each of the cell lines (MCF-7 and MCF-7/ADR-RES) having different donors. The other laboratories—American Type Culture Collection (Rockville, MD) used both RFLP and amplification fragment length polymorphism (AmpFLP) methods, and Children's Hospital of Michigan Cell Culture Laboratory (Detroit, MI) used the AmpFLP method—reached the same conclusions. Based on the reports from these DNA fingerprinting analyses, we have concluded that the preponderance of the information available suggests that the MCF-7/ADR-RES multidrug-resistant cell line that is included in the DTP screening program is not related to the MCF-7 cell line that is a part of the screening panel. **Thus, we have changed the nomenclature of the MCF-7/ADR-RES multidrug-resistant cell line.** The new designation of this cell line is **NCI/ADR-RES**. This nomenclature change will soon appear in all DTP databases, including the Worldwide Web. The DTP Web site address is: <http://dtp.nci.nih.gov>

Irrespective of its origin, this cell line has served as a valuable sentinel for compounds interacting with the multidrug-resistant mechanism (5).

DOMINIC A. SCUDIERO  
ANNE MONKS  
EDWARD A. SAUSVILLE

#### References

- (1) Monks A, Scudiero D, Skehan P, Shoemaker R, Paull K, Vistica D, et al. Feasibility of a high-flux anticancer drug screen using a diverse panel of cultured human tumor cell lines. *J Natl Cancer Inst* 1991; 83:757-66.
- (2) Stinson SF, Alley MC, Kopp WC, Fiebig HH, Mullendore LA, Pittman AF, et al. Morphological and immunocytochemical characteristics of human tumor cell lines for use in a disease-orientated anticancer drug screen. *Anticancer Res* 1992; 12:1035-53.
- (3) Wu L, Smythe AM, Stinson SF, Mullendore LA, Monks A, Scudiero DA, et al. Multidrug-resistant phenotype of disease-orientated panels of human tumor cell lines used for anticancer drug screening. *Cancer Res* 1992;52:3029-34.
- (4) Lee JS, Paull K, Alvarez M, Hose C, Monks A, Grever M, et al. Rhodamine efflux patterns predict P-glycoprotein substrates in the National Cancer Institute drug screen. *Mol Pharmacol* 1994; 46:627-38.
- (5) Alvarez M, Paull K, Monks A, Hose C, Lee JS, Weinstein J, et al. Generation of a drug resistance profile by quantitation of *mdr-1*/P-glycoprotein in the cell lines of the National Cancer Institute Anticancer Drug Screen. *J Clin Invest* 1995; 95:2205-14.

#### Notes

*Affiliations of authors:* D. A. Scudiero, A. Monks, Science Applications International Corp., National Cancer Institute at Frederick, Frederick, MD; E. A. Sausville, Developmental Therapeutics Program, Division of Cancer Treatment, Diagnosis, and Centers, National Cancer Institute, Bethesda, MD.

*Correspondence to:* Dominic A. Scudiero, Ph.D., Science Applications International Corp., National Cancer Institute at Frederick, Box B, Bldg. 432, Frederick, MD 21702-1201.

<b>NONHUMAN IN VITRO CELL LINES</b>					
<b>Designation</b>	<b>Species</b>	<b>Histologic Type</b>	<b>Tissue of Origin</b>	<b>Growth Medium</b>	<b>Remarks</b>
CHO 1C T6	Hamster	Normal	Ovary	F12	
B16F <sub>1</sub>	Mouse	Melanoma	Ear (B16)	EMEM	From Fidler
B16F <sub>10</sub>	Mouse	Melanoma	Lung met.	EMEM	From Fidler; high lung met.
B16F <sup>Lr6</sup>	Mouse	Melanoma	Lung met.	EMEM	From Fidler; low lung met.
B16BL-6	Mouse	Melanoma	Bladder met.	EMEM	From Fidler; intermediate lung met.
BALB/c 3T3	Mouse	Normal	Embryo	Dulbecco	
C3HIOT 1/2	Mouse				No info
Colon 26	Mouse	Carcinoma	Colon	RPMI 1640	
EL-4	Mouse	Lymphoma			
FBL-3	Mouse	Leukemia			
Lewis Lung	Mouse	Carcinoma	Lung	EMEM	
L1210/MRI	Mouse	Leukemia	Ascites	Fischer's	
L5178Y(R)/MRI	Mouse	Leukemia	Ascites	Fischer's	
MPC-11	Mouse	Myeloma			
M5076	Mouse	Reticulum cell sarcoma		RPMI 1640	
P3X63	Mouse				No info
P388	Mouse	Leukemia	Ascites	RPMI 1640	
P388/ADR	Mouse	Leukemia	Ascites	RPMI 1640	
PAN 02	Mouse	Adenocarcinoma	Pancreas	RPMI 1640	
YAC	Mouse	Lymphoma		EMEM	
K-1735	Mouse	Melanoma		EMEM	
UV-2237	Mouse	Fibrosarcoma		EMEM	
MADB 106	Rat				
MADB 200	Rat				

## **YEAST STRAINS**

YEAST STRAINS USED FOR NCI COMPOUND SCREENING		
SPY #	Relevant Mutation(s)	Complete Genotype
50636	<i>rad52</i>	<i>MAT<math>\alpha</math> rad52<math>\Delta</math>URA3 erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50644	none (wild-type control)	<i>MAT<math>\alpha</math> erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50648	<i>rad50</i>	<i>MAT<math>\alpha</math> rad50<math>\Delta</math>kan<sup>r</sup> ade2 ade3 leu2 ura3 trp1 cyh2</i>
50649	<i>mlh1 rad18</i>	<i>MAT<math>\alpha</math> mlh1<math>\Delta</math>TRP1 rad18<math>\Delta</math>LEU2 erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2 (trp1?)</i>
50650	<i>mgt1</i>	<i>MAT mtg1<math>\Delta</math>kan<sup>r</sup> erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50652	<i>rad50</i>	<i>MAT<math>\alpha</math> rad50<math>\Delta</math>kan<sup>r</sup> erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50654	<i>mec2-1</i>	<i>MAT<math>\alpha</math> mec2-1 erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50740	<i>rad14</i>	<i>MAT<math>\alpha</math> rad14<math>\Delta</math>kan<sup>r</sup> erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG::URA3::hisG ade2 ade3 leu2 ura3 cyh2</i>
50745	<i>sgs1 mgt1</i>	<i>MAT<math>\alpha</math> sgs1<math>\Delta</math>LEU2 mgt1kan<sup>r</sup> erg6<math>\Delta</math>LEU2 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 ura3 cyh2</i>
50768	<i>GPDp-CLN2</i>	<i>MAT<math>\alpha</math> URA3-GPDp-CLN2 erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50771	<i>GPDp-CLN2 rad14</i>	<i>MAT<math>\alpha</math> URA3-GPDp-CLN2 rad14<math>\Delta</math>kan<sup>r</sup> erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 ura3 cyh2 trp1</i>
50779	<i>bub3</i>	<i>MAT<math>\alpha</math> bub3<math>\Delta</math>URA3 erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 ura3 cyh2 trp1</i>
50780	none (wild-type control)	<i>MAT<math>\alpha</math> erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>
50834	<i>mlh1</i>	<i>MAT<math>\alpha</math> mlh1<math>\Delta</math>TRP1 erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 ura3 cyh2</i>
50835	<i>sgs1</i>	<i>MAT<math>\alpha</math> sgs1<math>\Delta</math>LEU2 erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 ura3 cyh2</i>
50891	<i>rad18</i>	<i>MAT<math>\alpha</math> rad18<math>\Delta</math>URA3 erg6<math>\Delta</math>TRP1 pdr1<math>\Delta</math>LEU2 pdr3<math>\Delta</math>hisG ade2 ade3 leu2 trp1 ura3 cyh2</i>

Notes:

Store at -70°C to -80°C. To establish working stock: scrape frozen culture with a wooden applicator stick and apply sample to agar-containing media (vials should remain frozen).

All strains are derived from L. Hartwell laboratory strains in the A364a genetic background.

The *erg6 pdr1 pdr3* mutations in all strains serve to make yeast more sensitive to a variety of compounds.

The allele present at the *TRP1* locus is unknown for SPY50649 (strain is phenotypically Trp<sup>+</sup> by virtue of *TRP1* at the *MLH1* locus).

## INDEX

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
10-24	Mesothelioma	Hamster	<a href="#">20</a>
102A	Unknown	Mouse	<a href="#">41</a>
10838	Seminoma	Hamster	<a href="#">20</a>
10 Lym-4	Negative Spleen	Rat	<a href="#">55</a>
11095	Prostate	Rat	<a href="#">52</a>
11348P	Pulmonary Squamous Cell Carcinoma	Hamster	<a href="#">20</a>
11963V	Leiomyosarcoma	Hamster	<a href="#">20</a>
11 Lym-9	Lymphosarcoma	Rat	<a href="#">55</a>
1247	Mammary Adenocarcinoma	Mouse	<a href="#">41</a>
13762	Mammary	Rat	<a href="#">52</a>
13762-FS	Fibrosarcoma	Rat	<a href="#">52</a>
1382J	Liver Carcinoma	Hamster	<a href="#">20</a>
13 Pr-5	Prostatic Carcinoma, Undifferentiated	Rat	<a href="#">55</a>
14 Lym-5	Lymphosarcoma Stimulated	Rat	<a href="#">55</a>
14 Pr-5	Prostatic Carcinoma	Rat	<a href="#">55</a>
15 Pr-2	Prostatic Adenocarcinoma	Rat	<a href="#">55</a>
16 Morris	Hepatoma	Rat	<a href="#">51</a>
16 Pr-3	Prostatic Adenocarcinoma	Rat	<a href="#">55</a>
17 Lym-4	Lymphosarcoma, implant required	Rat	<a href="#">55</a>
17 Lym-5	Leukemia	Rat	<a href="#">55</a>
18 Lym-6	Lymphosarcoma	Rat	<a href="#">55</a>
19 Lym-3	Lymphosarcoma	Rat	<a href="#">55</a>
19 Pr-19	Prostatic Fibroadenoma	Rat	<a href="#">55</a>
1 Cvx-34A(1)	Cervical Carcinoma	Rat	<a href="#">54</a>
1 Cvx-44Z	Cervical Carcinoma	Rat	<a href="#">54</a>
1 Lym-206	Lymphoma	Rat	<a href="#">54</a>
1 Lym-209 (A)	Lymphoma	Rat	<a href="#">54</a>
1 Lym-214	Lymphosarcoma	Rat	<a href="#">54</a>
1 Og-3	Osteogenic Sarcoma	Rat	<a href="#">54</a>
1 Pan-14Ax(1)	Adenocarcinoma	Rat	<a href="#">54</a>
1 Sal-23(2)	Salivary Gland, Secretory Tumor	Rat	<a href="#">54</a>
1 Tes-13E	Leydig Cell Carcinoma	Rat	<a href="#">54</a>
1 TES-15E	Leydig Cell Carcinoma	Rat	<a href="#">54</a>
20 Lym-3	Lymphosarcoma	Rat	<a href="#">55</a>
20 Morris	Hepatoma	Rat	<a href="#">51</a>
20 Pr-1	Prostatic Fibroadenoma	Rat	<a href="#">55</a>
21 Pr-9	Prostatic Carcinoma	Rat	<a href="#">56</a>
22047	Adenocarcinoma	Hamster	<a href="#">20</a>
22 Pr-8	Prostatic Adenocarcinoma	Rat	<a href="#">56</a>
2309V	Pancreatic Islet Cell Adenocarcinoma	Hamster	<a href="#">20</a>
23 Methapyrilene	Hepatocellular Carcinoma	Rat	<a href="#">52</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
23 Pr-7	Prostatic Carcinoma	Rat	<a href="#">56</a>
24 Pr-2	Prostatic Carcinoma	Rat	<a href="#">56</a>
25 Pr-3	Prostatic Adenocarcinoma	Rat	<a href="#">56</a>
293TT	Kidney	NIH Licensed Cell Lines	<a href="#">61</a>
2982	Olfactory Neuroblastoma	Rat	<a href="#">52</a>
29 Methapyrilene	Hepatocellular Carcinoma	Rat	<a href="#">52</a>
2 Lym-11(a)	Metaplastic, Adenocarcinoma Fibroblast Overgrowth	Rat	<a href="#">54</a>
2-Pan-6A	Pituitary Adenoma	Rat	<a href="#">54</a>
2-Pr-7A	Prostatic Adenocarcinoma	Rat	<a href="#">54</a>
2 Pr-9F	Prostatic Adenocarcinoma	Rat	<a href="#">54</a>
2 Pr-12	Prostatic Adenocarcinoma	Rat	<a href="#">54</a>
2 Pr-112Bx(1)	Prostatic Carcinoma Scirrhus	Rat	<a href="#">54</a>
2 Pr-114B	Prostatic Adenocarcinoma	Rat	<a href="#">54</a>
2 Pr-121D(1)	Prostatic Carcinoma, Secretory	Rat	<a href="#">54</a>
2 Pr-121D(1)R	Prostatic Carcinoma, Secretory	Rat	<a href="#">54</a>
2 Sk-103	Melanoma	Rat	<a href="#">54</a>
2 Ut-10(5)	Fibroma	Rat	<a href="#">54</a>
33 Methapyrilene	Hepatocellular Carcinoma	Rat	<a href="#">52</a>
36230 TLT	Hemangioidenothelioma	Mouse	<a href="#">41</a>
36257 TTT	Fibrosarcoma	Mouse	<a href="#">41</a>
38290 TTT	Fibrosarcoma	Mouse	<a href="#">42</a>
3924A	Hepatoma	Rat	<a href="#">51</a>
3 Kid-13	Kidney Adenocarcinoma	Rat	<a href="#">54</a>
3 Lym-19	Lymphosarcoma	Rat	<a href="#">54</a>
3M2N	Mammary Squamous Cell Carcinoma	Rat	<a href="#">52</a>
42021 TCT	Hemangioendothelioma	Mouse	<a href="#">42</a>
42022 TST	Hemangioendothelioma	Mouse	<a href="#">42</a>
42052 TST	Hemangioendothelioma	Mouse	<a href="#">42</a>
42076 TST	Hemangioendothelioma	Mouse	<a href="#">42</a>
44316 LTST	Hemangioendothelioma	Mouse	<a href="#">42</a>
44316 TST	Hemangioendothelioma	Mouse	<a href="#">42</a>
44347 TST	Hemangioendothelioma	Mouse	<a href="#">42</a>
44 Morris	Hepatoma	Rat	<a href="#">51</a>
46362 TTT	Fibrosarcoma	Mouse	<a href="#">42</a>
46363 TTT	Fibrosarcoma	Mouse	<a href="#">42</a>
4671	Pancreatic Duct Adenocarcinoma	Hamster	<a href="#">20</a>
4 Pan-6	Adenocarcinoma	Rat	<a href="#">54</a>
4 Sk-3A(3)Z	Squamous Cell Carcinoma	Rat	<a href="#">55</a>
4 Ut	Hemaniosarcoma	Rat	<a href="#">55</a>
4 Ut-6(2)	Fibrosarcoma	Rat	<a href="#">55</a>
50636		Yeast Strains	<a href="#">68</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
50644		Yeast Strains	<a href="#">68</a>
50648		Yeast Strains	<a href="#">68</a>
50649		Yeast Strains	<a href="#">68</a>
50650		Yeast Strains	<a href="#">68</a>
50652		Yeast Strains	<a href="#">68</a>
50654		Yeast Strains	<a href="#">68</a>
50740		Yeast Strains	<a href="#">68</a>
50745		Yeast Strains	<a href="#">68</a>
50768		Yeast Strains	<a href="#">68</a>
50771		Yeast Strains	<a href="#">68</a>
50779		Yeast Strains	<a href="#">68</a>
50780		Yeast Strains	<a href="#">68</a>
50834		Yeast Strains	<a href="#">68</a>
50835		Yeast Strains	<a href="#">68</a>
50891		Yeast Strains	<a href="#">68</a>
5123 Morris	Morris Hepatoma	Rat	<a href="#">51</a>
5 Pan-7	Undifferentiated Pancreatic Carcinoma	Rat	<a href="#">55</a>
5 Sal	Undifferentiated Carcinoma	Rat	<a href="#">55</a>
5 Sk-3	Melanoma	Rat	<a href="#">55</a>
5 Ut-2	Uterine Adenocarcinoma	Rat	<a href="#">55</a>
68-2	Alveolar/Bronchiolar Carcinoma	Rat	<a href="#">52</a>
6973P	Leiomyosarcoma	Hamster	<a href="#">20</a>
6C3HED	Lymphosarcoma	Jackson Lab Mouse	<a href="#">44</a>
6C3HED (Gardner)	Lymphosarcoma	Mouse	<a href="#">41</a>
6C3HED/AR Res.	Lymphosarcoma	Mouse	<a href="#">41</a>
6 Pan-4	Undifferentiated Pancreatic Carcinoma	Rat	<a href="#">55</a>
70429	Plasmacytoma	Mouse	<a href="#">42</a>
70429/Azaserine (NSC-3425)	Plasmacytoma	Mouse	<a href="#">42</a>
7777 Morris	Morris Hepatoma	Rat	<a href="#">51</a>
7800 Morris	Morris Hepatoma	Rat	<a href="#">51</a>
786-0	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
7 Ut-13	Endometrial Adenocarcinoma	Rat	<a href="#">55</a>
8721R	Renal Carcinoma	Hamster	<a href="#">20</a>
8746Q	Uterine Adenocarcinoma	Hamster	<a href="#">20</a>
8999 Morris	Morris Hepatoma	Rat	<a href="#">51</a>
8 Lym-9(1)	Lymphosarcoma	Rat	<a href="#">55</a>
8 Lym-108(1)	Lymphatic Leukemia	Rat	<a href="#">55</a>
91632	Reticulum Cell Sarcoma	Mouse	<a href="#">42</a>
9242	Parotid Acinar Cell Adenocarcinoma	Hamster	<a href="#">20</a>
9618A	Hepatoma	Rat	<a href="#">51</a>
9618A Morris	Hepatoma	Rat	<a href="#">51</a>
9A Ascites	Spontaneous Ascites	Rat	<a href="#">49</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
9 Lym-23	Lymphosarcoma	Rat	<a href="#">55</a>
A1011	Unknown	Rat	<a href="#">49</a>
A1131-AR	Unknown	Rat	<a href="#">49</a>
A1138-AL	Unknown	Rat	<a href="#">49</a>
A1140-CL-10	Unknown	Rat	<a href="#">49</a>
A2780	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
A498	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
A546 (DMBZ)		Rat	<a href="#">49</a>
A549	Nonsmall Cell	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
A704	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
A920 (Tetramin)		Rat	<a href="#">49</a>
AA Ascites	Spontaneous Ascites	Rat	<a href="#">49</a>
ACHN	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
Adenocarcinoma 755 (CA755, Bagg-Jackson, Adenocarcinoma)	Mammary Adenocarcinoma	Mouse	<a href="#">31</a>
ADJ-PC-6	Plasmacytoma	Mouse	<a href="#">31</a>
ASB XIV	Pulmonary Squamous Cell Carcinoma	Mouse	<a href="#">31</a>
AT	Adrenal	Mouse	<a href="#">31</a>
ATC 64	Thyroid Carcinoma	Rat	<a href="#">49</a>
AtT/20	Anterior Pituitary	Mouse	<a href="#">31</a>
Attenuated Resistant	Unknown	Rat	<a href="#">49</a>
B16	Melanoma (amelanotic)	Jackson Lab Mouse	<a href="#">44</a>
B16BL-6	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
B16F <sup>1</sup>	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
B16F <sup>10</sup>	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
B16F <sup>Lr6</sup>	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
BALB/c 3T3	Normal	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
BL12 Sensitive	Lymphosarcoma	Mouse	<a href="#">31</a>
BL12/Hc Ra	Lymphosarcoma	Mouse	<a href="#">31</a>
BOW-G	Melanosarcoma	Human	<a href="#">16</a>
Brown-Pearce	Carcinoma (Epithelioma)	Rabbit	<a href="#">47</a>
BT/M520	Fibrosarcoma	Rat	<a href="#">49</a>
BT-549	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
BW10232	Mammary Adenocarcinoma	Mouse	<a href="#">31</a>
BW10232	Mammary Adenocarcinoma	Jackson Lab Mouse	<a href="#">44</a>
BW7756	Hepatoma	Mouse	<a href="#">31</a>
BW7756	Hepatoma	Jackson Lab Mouse	<a href="#">44</a>
BW8685	Pituitary	Mouse	<a href="#">31</a>
BW8685	Pituitary	Jackson Lab Mouse	<a href="#">45</a>
BW8883	Pituitary	Mouse	<a href="#">31</a>
BW8883	Pituitary	Jackson Lab Mouse	<a href="#">44</a>
C1300	Round Cell (Neuroblastoma?)	Jackson Lab Mouse	<a href="#">45</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
C1498	Myelogenous Leukemia	Mouse	<a href="#">31</a>
C1498	Myeloid Leukemia	Jackson Lab Mouse	<a href="#">44</a>
C3HBA	Mammary Adenocarcinoma	Mouse	<a href="#">31</a>
C3HBA	Mammary Adenocarcinoma	Jackson Lab Mouse	<a href="#">44</a>
C3HIOT ½		NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
C4461	Lung Adenocarcinoma	Mouse	<a href="#">31</a>
C58/J Spontaneous	Leukemia	Mouse	<a href="#">31</a>
C95 Spleen/R		Mouse	<a href="#">31</a>
CA 20948	Pancreatic Acinar Carcinoma	Rat	<a href="#">49</a>
CA07/A	Colon Adenocarcinoma	Mouse	<a href="#">31</a>
CA36/Ara C (NSC-63878)	Colon Adenocarcinoma	Mouse	<a href="#">31</a>
CA51	Colon Adenocarcinoma	Mouse	<a href="#">31</a>
CaD1	Mammary Adenocarcinoma	Mouse	<a href="#">31</a>
CaD1	Mammary Adenocarcinoma	Jackson Lab Mouse	<a href="#">44</a>
CaD2	Mammary Adenocarcinoma	Mouse	<a href="#">31</a>
CAKI-1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
Carcinosarcoma	Carcinosarcoma (skin) (18-day embryos)	Rat	<a href="#">49</a>
CCO 1865	Mesothelioma	Rat	<a href="#">49</a>
CCO/1923	Hemangiosarcoma	Mouse	<a href="#">32</a>
CCRF-CEM	Leukemia	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
CCRF-SB	Leukemia	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
CE1460 MACA	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>
CH	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>
CHA-59	Bone, Osteosarcoma	Human	<a href="#">58</a>
CHO 1C T6	Normal	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
Cloudman Melanoma	Melanoma	Mouse	<a href="#">32</a>
COLO 205	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
Colon 26 (C26)	Carcinoma	Mouse	<a href="#">32</a>
Colon 26	Carcinoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
Colon 38	Carcinoma	Mouse	<a href="#">32</a>
COO-G	Mammary Carcinoma	Human	<a href="#">14</a>
COS-G	Lung, Papillary Carcinoma	Human	<a href="#">14</a>
Crocker Sarcoma		Mouse	<a href="#">32</a>
CSE	Fibrosarcoma	Rat	<a href="#">49</a>
CWR-22	Prostate, Adenocarcinoma	Human	<a href="#">18</a>
CX-1 (HT-29)	Colon, Adenocarcinoma	Human	<a href="#">15</a>
CX-2	Colon, Carcinoma	Human	<a href="#">15</a>
CX-3	Colon, Carcinoma	Human	<a href="#">15</a>
CX-5	Colon, Adenocarcinoma	Human	<a href="#">15</a>
D1T10		Mouse	<a href="#">32</a>
DAU	Burkitt's Lymphoma	Human	<a href="#">18</a>
DBA/2 Spontaneous Tumor M114	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
dbrB	Anaplastic Carcinoma	Mouse	<a href="#">32</a>
dbrB	Anaplastic Carcinoma	Jackson Lab Mouse	<a href="#">44</a>
DDB81-23	T cell Lymphoma	Rat	<a href="#">49</a>
DEAC-1	Mucoepidermoid Carcinoma	Human	<a href="#">18</a>
DEAC-7	Melanoma	Human	<a href="#">16</a>
DEL-G	Sarcoma	Human	<a href="#">18</a>
DL Wells-17	T cell Lymphoma	Rat	<a href="#">49</a>
DMBA	Mammary Adenocarcinoma	Rat	<a href="#">49</a>
DMS-114	Small Cell	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
DSL62-38	Pancreatic Tumor	Rat	<a href="#">49</a>
DU-145	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
DU4475	Mammary Carcinoma	Human	<a href="#">14</a>
Dunning Leukemia	Atypical Monocytic Leukemia	Rat	<a href="#">49</a>
Dunning Leukemia/ NSC-10107 (nitromin)	Atypical Monocytic Leukemia	Rat	<a href="#">49</a>
Dunning Leukemia/ NSC-13875 (HMM)	Atypical Monocytic Leukemia	Rat	<a href="#">49</a>
Dunning Leukemia/ NSC-17261 (benzoquinone)	Atypical Monocytic Leukemia	Rat	<a href="#">50</a>
Dunning Leukemia/ NSC-23892 (dimethylbenzimidazole)	Atypical Monocytic Leukemia	Rat	<a href="#">50</a>
Dunning Leukemia/ NSC-26980 (mitomycin C)	Atypical Monocytic Leukemia	Rat	<a href="#">50</a>
Dunning Leukemia/ NSC-29422 (thioguanosine)	Atypical Monocytic Leukemia	Rat	<a href="#">50</a>
Dunning Leukemia/ NSC-3088 (chlorambucil)	Atypical Monocytic Leukemia	Rat	<a href="#">49</a>
Dunning Leukemia/ NSC-45059 (o-acetyltetramin)	Atypical Monocytic Leukemia	Rat	<a href="#">50</a>
Dunning Leukemia/ NSC-51845 (cyclohexylamine)	Atypical Monocytic Leukemia	Rat	<a href="#">50</a>
Dunning Leukemia/ 755 (6-MP)	Atypical Monocytic Leukemia	Rat	<a href="#">49</a>
E Male Gross	Leukemia	Mouse	<a href="#">32</a>
Egg/Mouse Leukemia	Lymphocytic Leukemia	Mouse	<a href="#">32</a>
Ehrlich Ascites	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>
Ehrlich Ascites, Tetraploid	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>
Ehrlich Ascites/6-TG (NSC-752)	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>
EKVX	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
EL-4	Lymphoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
EL-4 Male	Lymphoma	Mouse	<a href="#">32</a>
ELL-G	Mammary Carcinoma	Human	<a href="#">14</a>
EMT-6	Mammary Adenocarcinoma	Mouse	<a href="#">32</a>
Ependyoblastoma (Zimmerman)	Ependyoblastoma	Mouse	<a href="#">32</a>
FB SAR (A)	Fibrosarcoma	Mouse	<a href="#">32</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
FB SAR (B)	Fibrosarcoma	Mouse	<a href="#">32</a>
FBL-3	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
FCB (C)	Transitional Cell Carcinoma of the Bladder	Mouse	<a href="#">32</a>
Fibrosarcoma	Fibrosarcoma	Hamster	<a href="#">20</a>
Flexner-Jobling	Seminal Vesicle Adenocarcinoma	Rat	<a href="#">50</a>
FO #1	Melanoblastoma	Human	<a href="#">16</a>
Fran Tumor	Ovarian Carcinoma	Rat	<a href="#">50</a>
Friend Virus Leukemia (FV01)	Reticulum Cell Sarcoma	Mouse	<a href="#">33</a>
Furth Tumor		Mouse	<a href="#">33</a>
FV01		Mouse	<a href="#">33</a>
Gardner Lymphosarcoma		Mouse	
GBT/W	Glial Tumor	Rat	<a href="#">50</a>
GL-1		Jackson Lab Mouse	<a href="#">44</a>
Glioma 26	Glioma	Mouse	<a href="#">33</a>
Glioma 261	Glioma	Mouse	<a href="#">33</a>
GOB-G	Colon, Adenocarcinoma	Human	<a href="#">15</a>
Gross Leukemia	Leukemia	Mouse	<a href="#">33</a>
Gross Mammary Adenocarcinoma	Mammary Adenocarcinoma	Mouse	<a href="#">33</a>
Guinea Pig Line 1 GP1	Hepatocarcinoma	Guinea Pig	<a href="#">22</a>
Guinea Pig Line 1 GP10	Hepatocarcinoma	Guinea Pig	<a href="#">22</a>
H-12	Mesothelioma	Hamster	<a href="#">20</a>
H23 (NCI-H23)	Lung, Nonsmall Cell, Adenocarcinoma	Human	<a href="#">15</a>
H2712	Mammary Adenocarcinoma	Mouse	<a href="#">33</a>
H2712	Mammary Adenocarcinoma	Jackson Lab Mouse	<a href="#">44</a>
H-372	Leydig	Rat	<a href="#">50</a>
H460 (NCI-H460)	Lung, Nonsmall Cell, Epid.	Human	<a href="#">15</a>
H-540	Leydig	Rat	<a href="#">50</a>
H6	Hepatoma	Mouse	<a href="#">33</a>
H6	Hepatoma	Jackson Lab Mouse	<a href="#">44</a>
H-75	Mesothelioma	Hamster	<a href="#">20</a>
Hageman		Mouse	<a href="#">33</a>
Harding-Passey	Melanoma	Mouse	<a href="#">33</a>
Hauschka Ascites Tumor	Unknown	Mouse	<a href="#">33</a>
HB Lynch-Fibroma 522	Fibroma	Rat	<a href="#">50</a>
HCC-2998	Colorectal Carcinoma	Human	<a href="#">15</a>
HCC-2998	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HCT-116	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HCT-15	Colon, Carcinoma	Human	<a href="#">15</a>
HCT-15	Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HE10734	Osteogenic Sarcoma	House	<a href="#">33</a>
HE10734/FR	Osteogenic Sarcoma	House	<a href="#">33</a>
HELA	Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
HEP-3	Epidermoid Carcinoma	Human	<a href="#">18</a>
Hepatoma 129 (HE129)	Hepatoma	Mouse	<a href="#">33</a>
Hepatoma 134 (HE134, Shear Hepatoma 134)	Hepatoma	Mouse	<a href="#">33</a>
Hepatoma NK		Rat	<a href="#">50</a>
HIG-G	Mammary Carcinoma	Human	<a href="#">14</a>
HL-3	Lymphoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HL-4	Lymphoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HL-60	Pro-myelocytic Leukemia	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HMC	Histiocytoma	Rat	<a href="#">50</a>
H-MESO-1	Lung, Mesothelioma	Human	<a href="#">15</a>
H-MESO-1	Mesothelioma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
H-MESO-1A	Lung, Mesothelioma	Human	<a href="#">15</a>
HOP-18	Large Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HOP-62	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HOP-92	Large Cell	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HP	Amelanotic Melanoma	Mouse	<a href="#">33</a>
HP	Melanoma (Amelanotic)	Jackson Lab Mouse	<a href="#">44</a>
HS 578T	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HS 913T	Mixed Cell	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
HS-1	Sarcoma	Human	<a href="#">18</a>
HT-29	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
IGR-OV1	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">58</a>
IRS 9802	Spindle Cell Sarcoma	Rat	<a href="#">50</a>
Iglesias	Ovarian Carcinoma	Rat	<a href="#">50</a>
Islet Cell	Pancreatic Adenocarcinoma	Hamster	<a href="#">20</a>
J-30237	Unknown	Mouse	<a href="#">33</a>
K-1735	Melanoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
K-562	Leukemia	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
KB-ADL #12	Epidermoid	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
Kid-27B	Kidney Adenocarcinoma	Rat	<a href="#">54</a>
Klein Tumor (TA3)	Mammary Adenocarcinoma	Mouse	<a href="#">33</a>
KLO-G	Colon, Adenocarcinoma	Human	<a href="#">15</a>
KM 20L2 (derivative of HT-29)	Colon, Adenocarcinoma	Human	<a href="#">15</a>
KM 20L2 (derivative of HT-29)	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
KM-12	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
Krebs 2 Carcinoma	Carcinoma of Inguinal Region	Mouse	<a href="#">33</a>
Krebs Ascites		Mouse	<a href="#">33</a>
L.T.W. (Furth)	Leydig	Rat	<a href="#">50</a>
L1210	Lymphoid Leukemia	Mouse	<a href="#">33</a>
L1210 FR3 DCM/R 100a	Lymphoid Leukemia	Mouse	<a href="#">35</a>
L1210 Variants		Mouse	<a href="#">35</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
L1210/5FU (NSC-19893)	Lymphoid	Mouse	<a href="#">34</a>
L1210/6MP (NSC-755)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/6MP/6TG	Lymphoid Leukemia	Mouse	<a href="#">35</a>
L1210/Anhydro-Ara C (NSC-145668)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/Ara-C (NSC-63878)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/BCNU (NSC-409962)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/C95	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/cis-DDP (NSC-119875)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/CTX (NSC-26271)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/DF8 (NSC-29630)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/DTIC (NSC-45388)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/FR8 (Folate Reductase)	Lymphoid Leukemia	Mouse	<a href="#">35</a>
L1210/FR8/DCM	Lymphoid Leukemia	Mouse	<a href="#">35</a>
L1210/Ftorafur (NSC-148958)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/HU (NSC-32065)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/L-PAM (NSC-8806)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/M-773	Lymphoid Leukemia	Mouse	<a href="#">35</a>
L1210/MeGAG (NSC-32946)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/MRI (NSC-153353)	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
L1210/MTX (NSC-740)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/NSC-19622	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/NSC-38280	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/TIC (NSC-60339)	Lymphoid Leukemia	Mouse	<a href="#">34</a>
L1210/TSC (NSC-729)	Lymphoid Leukemia	Mouse	<a href="#">33</a>
L18464	Lymphoma	Mouse	<a href="#">35</a>
L4946	Lymphocytic Leukemia	Mouse	<a href="#">35</a>
L5178Y	Leukemia	Mouse	<a href="#">35</a>
L5178Y (R)/MRI	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
LAF <sub>1</sub>	Adrenal Cortical Adenocarcinoma	Mouse	<a href="#">35</a>
LC-12	Pulmonary Squamous Cell Carcinoma	Mouse	<a href="#">35</a>
LC-18	Hepatocarcinoma	Rat	<a href="#">50</a>
Lewis Lung	Carcinoma	Mouse	<a href="#">35</a>
Lewis Lung	Carcinoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
Lewis Lung/PALA (NSC-224131)	Carcinoma	Mouse	<a href="#">35</a>
Lewis Sarcoma T241	Pleiomorphic	Mouse	<a href="#">35</a>
Line 1	Hepatocarcinoma	Guinea Pig	<a href="#">22</a>
Line 10	Hepatocarcinoma	Guinea Pig	<a href="#">22</a>
LLC-Luc-GFP (LL-LUC-POL2)	Lung Squamous Cell Carcinoma	Mouse	<a href="#">35</a>
LOVO	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
LOVO I	Colon, Adenocarcinoma	Human	<a href="#">15</a>
LOVO II	Colon, Adenocarcinoma	Human	<a href="#">16</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
LOX IMVI	Amelanotic Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
LPC-1	Plasmacytoma	Mouse	<a href="#">35</a>
LS402AX	Teratosarcoma	Mouse	<a href="#">35</a>
LSTRA	Lymphosarcoma	Mouse	<a href="#">35</a>
LSTRA/DTIC (NSC-45388)	Lymphosarcoma	Mouse	<a href="#">35</a>
LX-1	Lung, Undifferentiated Carcinoma	Human	<a href="#">14</a>
LXFL 529	Large Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
Lymphoma 8	Lymphoma	Rat	<a href="#">50</a>
Lymphosarcoma	Lymphosarcoma	Hamster	<a href="#">20</a>
M14	Amelanotic Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
M19-MEL	Amelanotic Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
M4898	Lung Adenocarcinoma	Mouse	<a href="#">35</a>
M5076	Reticulum Cell Sarcoma	Mouse	<a href="#">35</a>
M5076	Reticulum Cell Sarcoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
M5076/cis-DDP (NSC-119875)	Reticulum Cell Sarcoma	Mouse	<a href="#">36</a>
M5076/HMM (NSC-13875)	Reticulum Cell Sarcoma	Mouse	<a href="#">36</a>
M5076/L-PAM (NSC-8806)	Reticulum Cell Sarcoma	Mouse	<a href="#">36</a>
M5480	Testicular Carcinoma (Seminoma)	Mouse	<a href="#">36</a>
MA13C	Mammary Adenocarcinoma	Mouse	<a href="#">36</a>
MA16C	Mammary Adenocarcinoma	Mouse	<a href="#">36</a>
MA387	Fusiform Cell Sarcoma	Mouse	<a href="#">36</a>
MADB 106		NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
MADB 200		NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
Madison Lung (TA109)	Carcinoma	Mouse	<a href="#">36</a>
MALME-3M	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
MAMF2-TC	Fibrosarcoma	Rat	<a href="#">50</a>
Mastocytoma		Mouse	<a href="#">33</a>
MC-11	Mammary Adenocarcinoma	Mouse	<a href="#">36</a>
MC-5	Mammary Adenocarcinoma	Mouse	<a href="#">36</a>
MC-6 Female	Mammary Adenocarcinoma	Mouse	<a href="#">36</a>
MCF7	Mammary Carcinoma	Human	<a href="#">14</a>
MCF7	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
MCS-1	Mammary Adenocarcinoma	Mouse	<a href="#">36</a>
MDA-MB-231	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
MDA-MB-435	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
MDA-MB-436	Mammary Carcinoma	Human	<a href="#">14</a>
MDA-MB-468	Mammary Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
Mecca (ME61, MLS)	Lymphosarcoma	Mouse	<a href="#">36</a>
Melanoma	Melanotic Melanoma	Hamster	<a href="#">20</a>
MET 149-2	Adenocarcinoma	Rat	<a href="#">50</a>
METH-A	Sarcoma	Mouse	<a href="#">36</a>
MLS		Mouse	<a href="#">36</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
MNU-Buffalo	Mammary Carcinoma	Rat	<a href="#">51</a>
Moloney Sarcoma (SV-122-TR4)	Sarcoma	Mouse	<a href="#">36</a>
MOLT-4	Leukemia	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
Moore Sarcoma #1	Sarcoma	Rat	<a href="#">51</a>
MOPC-104	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-112	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-113	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-114	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-116	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-118	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-121	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-123	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-129	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-132	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-140	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-141	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-157	Plasmacytoma	Mouse	<a href="#">38</a>
MOPC-17	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-172	Plasmacytoma	Mouse	<a href="#">38</a>
MOPC-173	Plasmacytoma	Mouse	<a href="#">38</a>
MOPC-209	Plasmacytoma	Mouse	<a href="#">38</a>
MOPC-21	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-28	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-30	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-31	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-4	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-41	Plasmacytoma	Mouse	<a href="#">36</a>
MOPC-46	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-47	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-48	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-49	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-51	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-61	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-63	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-67	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-69	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-70	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-78	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-88	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-91	Plasmacytoma	Mouse	<a href="#">37</a>
MOPC-96	Plasmacytoma	Mouse	<a href="#">37</a>
Morris Hepatomas	HepATOMA	Rat	<a href="#">51</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
MPC-1	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-11	Myeloma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
MPC-15	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-2	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-25	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-26	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-31	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-36	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-37	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-40	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-42	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-44	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-48	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-49	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-59	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-60	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-63	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-64	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-67	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-73	Plasmacytoma	Mouse	<a href="#">38</a>
MPC-H	Plasmacytoma	Mouse	<a href="#">38</a>
MRI-H-121	Kidney, Carcinoma	Human	<a href="#">17</a>
MRI-H-121B	Melanoma, Malignant	Human	<a href="#">16</a>
MRI-H-130	Cervix, Squamous Cell Carcinoma	Human	<a href="#">16</a>
MRI-H-147	Endometrium, Carcinoma, Müllerian Duct	Human	<a href="#">17</a>
MRI-H-1579	Prostate Adenocarcinoma	Human	<a href="#">18</a>
MRI-H-165	Lung, Squamous Cell Carcinoma	Human	<a href="#">15</a>
MRI-H-166	Kidney, Transitional Cell Carcinoma	Human	<a href="#">17</a>
MRI-H-171	Endometrium, Carcinoma	Human	<a href="#">17</a>
MRI-H-177	Cervix, Squamous Cell Carcinoma	Human	<a href="#">16</a>
MRI-H-1834	Ovarian Carcinoma	Human	<a href="#">17</a>
MRI-H-186	Cervix, Invasive, Large Cell, Nonkeratinizing, Squamous Cell Carcinoma	Human	<a href="#">16</a>
MRI-H-187	Melanoma, Epitheloid, Melanotic	Human	<a href="#">16</a>
MRI-H-194	Colon, Adenocarcinoma	Human	<a href="#">15</a>
MRI-H-196	Cervix, Poorly Differentiated Squamous Cell Carcinoma	Human	<a href="#">16</a>
MRI-H-207	Ovary, Undifferentiated Carcinoma	Human	<a href="#">17</a>
MRI-H-215	Cervix, Invasive, Large Cell, Nonkeratinizing, Poorly Differentiated, Epidermoid Carcinoma	Human	<a href="#">17</a>
MRI-H-220	Endometrium, Carcinoma	Human	<a href="#">17</a>
MRI-H-221	Melanoma, Malignant	Human	<a href="#">16</a>
MRI-H-227	Ovarian Adenocarcinoma	Human	<a href="#">17</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
MRI-H-250	Colon, Carcinoma	Human	<a href="#">16</a>
MRI-H-253	Endometrium, Carcinoma	Human	<a href="#">17</a>
MRI-H-254	Stomach, Adenocarcinoma	Human	<a href="#">18</a>
MRI-H-255	Melanoma	Human	<a href="#">16</a>
MRI-H-258	Ovarian Adenocarcinoma	Human	<a href="#">17</a>
MRI-H-266	Lung, Poorly Differentiated Carcinoma	Human	<a href="#">15</a>
MRI-H-273	Ovarian Carcinoma	Human	<a href="#">17</a>
MS-2	Sarcoma	Mouse	<a href="#">38</a>
MST	Mast Cell	Mouse	<a href="#">38</a>
MT/W449	Mammary Adenocarcinoma	Rat	<a href="#">51</a>
MT/W9	Mammary Adenocarcinoma	Rat	<a href="#">51</a>
MtT	Anterior Pituitary	Rat	<a href="#">51</a>
Murphy-Sturm Lymphosarcoma (MSL)	Lymphosarcoma	Rat	<a href="#">51</a>
MX-1	Mammary Carcinoma	Human	<a href="#">14</a>
MX-1	Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
MX-2	Mammary Carcinoma	Human	<a href="#">14</a>
MXT	Mammary Ductal	Mouse	<a href="#">38</a>
NBW-37	T Cell Lymphoma	Rat	<a href="#">51</a>
NC-37	Normal	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI/ADR-RES	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H125	Adenosquamous Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H226	Squamous Cell	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H23	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H2887	Adenocarcinoma	NIH Licensed Cell Lines	<a href="#">61</a>
NCI-H292	Adenosquamous Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H3122	Adenocarcinoma	NIH Licensed Cell Lines	<a href="#">61</a>
NCI-H322M	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H3255	Adenocarcinoma	NIH Licensed Cell Lines	<a href="#">61</a>
NCI-H358M	Bronchiolo-Alveolar Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H460	Large Cell	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H522	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H69	Small Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H82	Small Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
NCI-H838	Adenocarcinoma	NIH Licensed Cell Lines	<a href="#">61</a>
Nettesheim Lung	Squamous Cell Lung Carcinoma	Mouse	<a href="#">39</a>
NIS-G	Melanosarcoma	Human	<a href="#">16</a>
Nitrosamine-Induced Hepatoma	Hepatoma	Guinea Pig	<a href="#">22</a>
NK-Lymphoma	Lymphoma	Mouse	<a href="#">38</a>
Novikoff Hepatoma	Hepatoma	Rat	<a href="#">51</a>
NS104	Rhabdomyosarcoma	Rat	<a href="#">51</a>
OGL-G	Sarcoma, Spindle Cell, Periosteal Osteogenic	Human	<a href="#">18</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
OR-16-3	Thymus Tumor	Rat	<a href="#">51</a>
OV		Human <i>In Vitro</i> Cell Lines	<a href="#">59</a>
OVCAR-3	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
OVCAR-4	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
OVCAR-5	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
OVCAR-8	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
P1534	Lymphocytic Leukemia	Mouse	<a href="#">40</a>
P1798	Lymphosarcoma	Mouse	<a href="#">40</a>
P1798/CR-JS	Lymphoma	Mouse	<a href="#">40</a>
P1798/CS-JS	Lymphoma	Mouse	<a href="#">40</a>
P288	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P288/MTX (NSC-740)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
P388/5-Azacytidine (NSC-102816)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/5FU (NSC-19893)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/Acivicin (NSC-163501)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/ActinomycinD (NSC-3053)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/ADR (NSC 123127)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/ADR	Leukemia	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
P388/Amsacrine (NSC-249992)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/Ara-A + 2'dcF (NSC-404241 + NSC-218321)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/Ara-C (NSC-63878)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/BCNU (NSC-409962)	Lymphocytic Leukemia	Mouse	<a href="#">40</a>
P388/CPA (NSC-26271)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/Daunomycin (NSC-82151)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/DON (NSC-7365)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/L-Alanosine (NSC-153353)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/L-PAM (NSC-8806)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/Mitoxantrone (NSC-301739)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/MTX (NSC-740)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P388/VCR (NSC-67574)	Lymphocytic Leukemia	Mouse	<a href="#">39</a>
P3X63		NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
P815 (Hageman Mastocytoma)	Mast Cell Leukemia	Mouse	<a href="#">40</a>
P815/VLB (NSC-49842)	Mast Cell Leukemia	Mouse	<a href="#">40</a>
Pan #1 (Fortner)	Pancreatic Duct Adenocarcinoma	Hamster	<a href="#">20</a>
PAN 02	Pancreas	Mouse	<a href="#">40</a>
PAN 02	Adenocarcinoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
PAN 03	Pancreas	Mouse	<a href="#">40</a>
Papillary Carcinoma		Mouse	<a href="#">38</a>
PC-3	Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
PC-3/M	Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
PR1C1T5/NSC-45388	Lymphoid Leukemia	Mouse	<a href="#">40</a>
PR1SE1T5	Lymphoid Leukemia	Mouse	<a href="#">40</a>
PR1SE1T5/NSC-45388	Lymphoid Leukemia	Mouse	<a href="#">40</a>
R-26	Unknown	Mouse	<a href="#">40</a>
R3149	Leukemia	Rat	<a href="#">52</a>
R3230AC	Mammary Adenocarcinoma	Rat	<a href="#">52</a>
R3259	Giant Cell Sarcoma	Rat	<a href="#">51</a>
R3327	Prostate	Rat	<a href="#">52</a>
R3327 (Pap)	Prostate	Rat	<a href="#">52</a>
R35	Mammary Adenocarcinoma	Rat	<a href="#">51</a>
R-46	Unknown	Mouse	<a href="#">40</a>
R-53	Unknown	Mouse	<a href="#">40</a>
R-74	Unknown	Mouse	<a href="#">40</a>
RBL-5 (Rauscher Virus Induced Transplantable Tumor-5)	Leukemia	Mouse	<a href="#">40</a>
RC-2	Renal Adenocarcinoma	Mouse	<a href="#">40</a>
Reif-Allen Tumor	Thymoma	Mouse	<a href="#">40</a>
Rice 500	Leydig	Rat	<a href="#">51</a>
Rice D6	Leydig	Rat	<a href="#">51</a>
Riejoel	Thyroid Adenocarcinoma	Rat	<a href="#">51</a>
RNC 259	Pheochromocytoma	Rat	<a href="#">52</a>
RNC 288	Insulinoma	Rat	<a href="#">52</a>
RNK-16	LGL Leukemia	Rat	<a href="#">52</a>
RPC-20	Plasmacytoma	Mouse	<a href="#">40</a>
RPC-5	Plasmacytoma	Mouse	<a href="#">40</a>
RPC-9	Plasmacytoma	Mouse	<a href="#">40</a>
RPMI-7951	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
RPMI-8226	Leukemia	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
RXF 393 (available only to DTP, NCI)	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
RXF 631	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
S180	Pleomorphic Sarcoma	Jackson Lab Mouse	<a href="#">45</a>
S180 (Crocker, S III)	Pleomorphic Cell	Mouse	<a href="#">41</a>
S37	Pleomorphic Cell	Mouse	<a href="#">40</a>
S37	Pleomorphic Sarcoma	Jackson Lab Mouse	<a href="#">45</a>
S91	Melanoma (Melanotic)	Jackson Lab Mouse	<a href="#">44</a>
Sa 1	Spindle Cell Carcinoma	Mouse	<a href="#">41</a>
Sa D2	Fibrosarcoma	Mouse	<a href="#">41</a>
Sa D2	Fibrosarcoma	Jackson Lab Mouse	<a href="#">44</a>
Sal	Spindle-Cell Sarcoma	Jackson Lab Mouse	<a href="#">45</a>
SB #1 (Fortner)	Small Bowel Adenocarcinoma	Hamster	<a href="#">20</a>
SF 295	Glioblastoma	Human	<a href="#">18</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
SF-268	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SF-295	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SF-539	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
Shay Leukemia	Myelogenous Leukemia	Rat	<a href="#">52</a>
Shear Hepatoma 134		Mouse	<a href="#">41</a>
SHP-77	Small Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SJL/JW	Reticulum Cell Sarcoma	Mouse	<a href="#">41</a>
SK-MEL-2	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SK-MEL-28	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SK-MEL-5	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SK-MES-1	Squamous Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SK-OV-3	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SMT-2A	Mammary Carcinoma	Rat	<a href="#">52</a>
SN12A1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SN12C	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SN12K1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SN12L1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SN12S1	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SNB-19	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SNB-7	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SNB-75	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SNB-78	Astrocytoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
Spontaneous Mammary	Mammary Adenocarcinoma	Mouse	<a href="#">41</a>
Spontaneous Adrenal	Adrenal	Mouse	<a href="#">41</a>
Spontaneous DBA/2 Mammary	Mammary Adenocarcinoma	Mouse	<a href="#">41</a>
SR	Lymphoma	Human <i>In Vitro</i> Cell Lines	<a href="#">60</a>
SV-122-TR4		Mouse	<a href="#">41</a>
SW-613	Mammary Carcinoma	Human	<a href="#">14</a>
SW-620		Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
SWA-G	Ovarian Carcinoma	Human	<a href="#">17</a>
Swarm	Chondrosarcoma	Rat	<a href="#">52</a>
T1699	Mammary Adenocarcinoma	Mouse	<a href="#">41</a>
T1699	Mammary Adenocarcinoma	Jackson Lab Mouse	<a href="#">44</a>
T1703	Mammary Adenocarcinoma	Mouse	<a href="#">41</a>
T1703	Mammary Adenocarcinoma	Jackson Lab Mouse	<a href="#">44</a>
T-47D (not to or for commercial use)	Mammary	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
TA109		Mouse	<a href="#">41</a>
TA3		Mouse	<a href="#">41</a>
TG1-4	Mesothelioma	Hamster	<a href="#">20</a>
TK-10	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
TR.CLXXXVIII	Melanoma	Rat	<a href="#">52</a>
TR.DCCXLIII	Pituitary	Rat	<a href="#">52</a>

ALPHABETICAL TUMOR INDEX			
Designation	Histologic Type	Species	Page No.
TRI-G	Melanoma	Human	<a href="#">16</a>
TS1-4	Epidermoid Carcinoma	Hamster	<a href="#">20</a>
U-251	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
UACC-257	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
UACC-62	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
UCSD 242L	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
UCSD 354L	Melanoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
UO-31	Renal Cell Carcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
UV-2237	Fibrosarcoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
VAN-G	Mammary Carcinoma	Human	<a href="#">15</a>
VX-2 (V2)	Skin Carcinoma	Rabbit	<a href="#">47</a>
Walker 256	Carcinosarcoma	Rat	<a href="#">52</a>
WIDR (derivative of HT-29)	Adenocarcinoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
WIL-G	Melanoma	Human	<a href="#">16</a>
X5563	Unknown	Mouse	<a href="#">41</a>
XF 498	Glioblastoma	Human <i>In Vitro</i> Cell Lines	<a href="#">61</a>
YAC	Lymphoma	NonHuman <i>In Vitro</i> Cell Lines	<a href="#">66</a>
Yoshida Hepatoma	Hepatoma	Rat	<a href="#">52</a>
Yoshida Sarcoma	Sarcoma	Rat	<a href="#">52</a>
YPC-1	Plasmacytoma	Mouse	<a href="#">41</a>
Zimmerman Ependymoblastoma		Mouse	<a href="#">41</a>